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                                                        ABSTRACT 
 
 
            Studies on a 50S Ribosomal Precursor Particle as a Substrate for ermE  
                       Methyltransferase Enzyme in Staphylococcus aureus 
 
 
                                                                 by 
  
                                                        Indira Pokkunuri 
 
 
Erythromycin is a macrolide antibiotic that inhibits not only mRNA translation but also 
50S ribosomal subunit assembly in bacterial cells. An important mechanism of 
erythromycin resistance is the methylation of 23S rRNA by erm methyl transferase 
enzymes. We are interested in investigating the true substrate for methylation because 
it is known from our work and the work of others that fully assembled 50S subunits are 
not substrates for methylation. We have published a model for 50S ribosomal subunit 
formation where, the precursor particle that accumulates in erythromycin treated cells is 
a target for methyl transferase activity. Current studies are aimed at investigating the 
role of the precursor particle as substrate for ermE methyltransferase activity and the 
competition between this enzyme and erythromycin for the 50S precursor particle. 
 
Slot-blot hybridization experiments have identified the presence of 23S rRNA in the 50S 
precursor region. Quantitation of the 23S rRNA in these blots also revealed that the 
percentage of the precursor increased as the concentration of erythromycin was 
increased in the growth media. Ribosomal proteins of S. aureus were studied by two-
dimensional gel electrophoresis.  Protein content of the 50S precursor particle was 
 3 
analyzed by MALDI-TOF. These studies have identified 16 50S ribosomal proteins in 
the precursor region.  
 
Methyltransferase assays showed that 50S precursor particle was a substrate for ermE 
methyltransferase. Importantly, RNA that is already assembled into 50S subunits was 
not a substrate for the enzyme. Inhibition curves showed that macrolide, lincosamide, 
and streptogramin B (MLSB) drugs bound to the precursor particle with similar affinity 
and inhibited the ermE methyltransferase activity. Competition experiments suggested 
that the enzyme can displace erythromycin from the 50S precursor particle and that erm 
methyltransferase has a lower association constant for the precursor particle compared 
to that of the erythromycin. This suggests that higher concentrations of erythromycin are 
needed to combat erm induced resistance.    
 
These studies shed light on the interaction of ermE methyltransferase and erythromycin 
in the clinically important pathogen S. aureus. 
         .   
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CHAPTER 1 
INTRODUCTION 
 
          For many years, antibiotics have been effective in the treatment of many 
infectious diseases caused by a range of pathogens, including Staphylococcus aureus 
(Marana et al. 1997). But the continuing increase in antibiotic resistance among 
bacteria has transformed some previously treatable diseases into new threat to public 
health ( Cohen 1994, Rubinstein 1994, Anderson 1999). The number of resistant 
bacterial strains keeps increasing and antibiotics are rapidly loosing their efficacy 
(Amabile-Cuevas 1995, Chu and Katz 1996). Consequently, there is an increasing 
need for an in- depth understanding of the antibiotic resistance mechanisms in this 
post-antibiotic era. 
          Ribosomes are the primary target for a majority of antibiotics (Marana et al. 
1997). Ribosomes are sophisticated molecular machines to ensure that the genetic 
information is reliably translated into proteins ( Liebold 1986, Garrett et al. 2000). The 
structure of the ribosome reflects its functional complexity. In bacteria, ribosomes 
consist of two ribonucleoprotein complexes, the small 30S subunit and the large 50S 
subunit. The 30S subunit is made up of 16S rRNA and 21 proteins, whereas the large 
50S subunit consists of 5S and 23S rRNA and 36 proteins.  
        S. aureus is a ubiquitous bacterium that causes infections in all age groups.           
Staphylococci are non-spore-forming Gram-positive bacteria that belong to the 
Micrococcaceae family. It is a major causative agent in surgical wound infections and 
other systemic infections like osteomyelitis, endocarditis, pneumonia, and septicemia  
 12 
(Cohen and Quinn 1982). A variety of clinical syndromes are associated with genetic 
elements harbored by S. aureus strains like RN -3985 and NZ-39  that encode certain 
toxins (Meissner  et.al. 1993, Parsonett and Marchette 1994). Examples include 
staphylococcal food poisoning and toxic shock syndrome. Also, S. aureus is the most 
frequently reported pathogen causing nosocomial infections in infants and children 
(Cabezudo and Wenzel 1982).  
            Macrolide antibiotics have been effective in treating the infections caused by S. 
aureus, Streptococcus, and other Gram-positive organisms. This class of antibiotics 
inhibit protein synthesis by binding in a stoichiometric fashion to the peptidyl 
transferase center (PTC) catalyzing the peptide bond formation in the 50S subunit of 
the bacterial ribosome (Vazquez 1979, Mazzei et al. 1993, Weisblum 1995). Although 
ribosomal proteins can affect the binding and action of ribosome-targeted antibiotics, 
the primary target of these antibiotics is rRNA (Cundliffe 1990).  But the therapeutic 
utility of macrolides has been severely compromised by the emergence of drug 
resistance in these pathogenic bacteria (Voss and Doebelling 1995). 
         Macrolides, together with two other related classes of antibiotics, lincosamides 
and streptogramins B, share overlapping binding sites on the 50S ribosomal subunit. 
They are together called MLSB antibiotics (Spahn and Prescott 1996) (Figure 1).  
 
 
 
 
 
   
 13 
 
A.                                                                      B. 
 
 
                                         C. 
                                       
   
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Structure of MLS antibiotics. (A) Erythromycin (Macrolide), (B) Lincomycin 
(Lincosamide), (C) Virginiamycin S (Streptogramin).  
 
             Structure probing studies of 23S rRNA with the antibiotics has revealed similar 
binding interactions between these compounds (Moazed and Noller 1987, Douthwaite 
1992, Kirillov 1999). Within the 23S rRNA, the binding site for MLS antibiotics is 
composed of domain V sequences near the PTC that serve as a channel for the  
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growing polypeptide chain (Figure 2). These drugs exhibit competitive binding to the 
50S subunits whereby binding of one class of drugs is competed by an excess of 
another class of drugs (DiGiambattista and Vanuffel 1986).  Bacterial cells resistant to 
one class of antibiotics can show cross-resistance to the other two classes (Leclercq 
1991, Leclercq and Courvalin 2002). Resistance to macrolide, lincosamide, and 
streptogramin B (MLSB) antibiotics comprises a resistance syndrome of bacteria widely 
distributed in nature called MLSB resistance (Duval 1985). 
 
                             
                                   
Figure 2 Secondary structure diagram of the peptidyl transferase loop and a loop from 
domain V of E. coli 23S rRNA along with the sequence numbers. Shown in this model is 
the site of action of erythromycin resistant methylase residue A2058 (Orange arrow).   
 
             Inhibition of protein synthesis by macrolides has two distinctive features 
(Gale 1981, Kirillov 1997). First, macrolides neither bind to nor inhibit the peptide-
forming activity (Pestka 1972, Anderson and Kurland 1987) of ribosomes that are 
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already engaged in protein synthesis. Second, in ribosomes that do not have nascent 
peptides bound, synthesis stops after the first 5 amino acids (Odom 1991).    
          Erythromycin is a 14-membered macrolide antibiotic that is effective against a 
variety of Gram-positive bacteria. Discovered in 1952, it was the first macrolide to 
enter clinical use, and it remains to this day one of the most widely used macrolides 
along with many of its derivates. It is produced in an actinomycetes species 
Streptomyces erythreus. As shown in Figure 1 it has a macrolactone ring to which 
two sugar residues L-Cladinose and D-Desosamine are attached through glycosidic 
bonds.                                                           
          The binding site for the macrolides is located on the large ribosomal subunit 
inside the nascent peptide exit tunnel near the PTC (Figure 3). The reactive groups of 
the desosamine sugar and the lactone ring mediate all the hydrogen-bond 
interactions of erythromycin with the PTC. But the shorter desosamine residue of the 
14- membered ring macrolides does not reach the peptidyl transferase center, which 
explains the lack of inhibitory effects of these drugs on the reaction of 
transpeptidization. The exit tunnel is formed primarily by 23S rRNA. It starts at the 
PTC and spans the entire body of the subunit finally opening at its back (Bernabeu 
and Lake 1982, Frank and Zhu 1995, Ban et al. 2000). 
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Figure 3 Global views of the macrolide binding site showing how they block the 
peptide exit tunnel of Haloarcula marismortui. (A) Macrolide Binding site: The top 
of the ribosome is rotated backward from the crown view so that the peptide exit 
tunnel (gray) with modeled peptide (orange ribbon) can be seen when the front 
half of the ribosome is removed. Ribosomal RNA is white and ribosomal proteins 
are light blue space-filling representations. The E-site tRNA (red sticks), A-site 
tRNA (purple sticks), and P-site tRNA (orange sticks) have been positioned using 
the coordinates from the 70S ribosome complex after superposition of 
corresponding 50S subunit atoms. PTC indicates peptidyl transferase center. 
Black arrows point to an opening between the peptidyl transferase center and the 
peptide exit tunnel where the macrolides (red) bind. The green atoms are the 
bases that interact with the macrolides.    
(B) Constriction. An alternate view up the exit tunnel, through the constriction, 
shows P- site (orange sticks) and A-site (purple sticks) substrates bound to the 
active sites. (C) Blockage. The opening shown in (B) is occluded by both the 
presence of macrolide (red) and the extended conformation of A 2103 (E. coli 
A2062) (green). Adapted from (Hansen et al. 2002)  
 
 
 
 
 
 
 
 
PTC 
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            Although originally conceived as an inert conduit for any nascent peptides, 
the tunnel is now considered as an active and dynamic functional entity (Gabashvili 
and Gregory  2001) that is relatively wide (avg. 150 Å). However, it contains a 
constriction of 100 Å formed by proteins L4 and L22, which is located at a short 
distance from PTC. Macrolides bind close to this constriction and pose a molecular 
road block for the growing peptide chain (Gabashvili and Gregory 2001, Schlunzen 
and Zarivach 2001, Hansen et al. 2002). In the presence of bound 14 or 15 
membered macrolides, polymerization of the first few amino acids proceeds 
unperturbed. Inhibition of polypeptide growth occurs only after it becomes long 
enough to reach the bound macrolide near the constriction. Inhibition of peptide 
elongation eventually results in the dissociation of peptidyl tRNA from the ribosome.   
        The length of the oligopeptide synthesized in the presence of macrolide 
antibiotics is determined by the extent to which substituents at position C5 position of 
the lactone ring penetrate the peptidyl transferase center. Erythromycin, which has a 
monosaccharide at position C5, permits the synthesis of peptides up to 8 amino acids 
long before the peptidyl tRNA is dropped off the ribosome.     
       There are several known mechanisms by which bacteria exhibit resistance to the 
inhibitory effects of macrolides. These fall into three main classes:  
(i) deficiency of macrolide entrance into the cell (Weisblum 1979, Lampson et al.1986), 
(ii) chemical inactivation of the macrolide (Arthur and Andremont 1987, Wiley 1987), 
(iii) absence of macrolide binding to the target site (Lai and Weisblum 1971, Duval 
1985). The latter mechanism of resistance to MLSB antibiotics is due to an alteration of 
their target site (Takashima 2003, Hansen et al 2006,) in the ribosome.  
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         The most frequently occurring mechanism of erythromycin resistance is the 
target site modification of A2058 by dimethylation (Weisblum 1995). A2058 is an 
important residue near the PTC for macrolide binding with its N1 and N6 forming two 
hydrogen bonds with the 2’OH of desosamine sugar of the macrolide. Any modification 
of this residue would diminish macrolide binding leading to resistance (Figure 2). 
Organisms that have multiple rRNA cistrons often become resistant by acquiring 
genes for enzymes that methylate N6 of A2058. This is because in these organisms 
resistance by point mutation in one gene is compensated by the wild type sequence in 
another gene whereas in organisms that have only one or two cistrons, resistance 
results from mutation of A2058 to G and from mutations in the other nucleotides near 
to the PTC that are critical for MLS binding (Vester 2001).  
            Erythromycin and related ribosomal inhibitors have two equivalent inhibitory 
effects on bacterial cells, inhibition of translation and inhibition of 50S ribosomal 
subunit assembly. Both activities of these drugs are responsible for their bactericidal 
effect in Gram-positive cells (Moazed and Noller 1987).      
           An understanding of the features of target sites is needed to understand the 
resistance mechanisms to antibacterial agents. A 3.1 Å X-ray crystal model of 
erythromycin with the 50S ribosomal subunit of Deinococcus radiodurans (Dr) 
provided important insights into the molecular basis of erythromycin binding to the 
ribosomes (Schlunzen et al. 2001). These crystal data indicate that macrolides attach 
in the peptide tunnel with the lactone ring about 25 Å from the subunit interface. The 
crystal structures reveal that the macrolides bind in a narrow part of the peptide exit 
tunnel at a site that lies between the peptidyl transferase center and the constriction in 
the tunnel near the proteins L4 and L22 and thereby occlude the lumen (Figure 4). 
 19 
This, in turn, prevents the extension of nascent polypeptide chains (Weisblum 1985, 
Gregory and Dahlberg 1999).  
   
                                      
Figure 4 Top view of the D. radiodurans 50S subunit.  Erythromycin (red) bound at the 
entrance of the tunnel is shown by white arrow. Yellow, ribosomal proteins; grey 23S 
rRNA; dark grey, 5S rRNA. Adapted from (Schlunzen et al. 2001). 
 
            Figure 5 depicts the detailed chemical interactions of erythromycin with 
ribosomes of Deinococcus radiodurans (Dr) as supported by the crystallographic 
studies. It shows that the 2’OH of the desosamine sugar forms hydrogen bonds at 
three positions: N6 and N1 of A 2041Dr (A2058 Ec) and N6 of A2042 Dr (A2059 Ec). 
The two hydrogen bonds between the 2’OH and the N1 and N6 of A2058 explain why 
this nucleotide is pivotal in macrolide binding, and also why dimethylation of N6 of 
A2058 is the most common mechanism of erythromycin resistance. The 
dimethylation of N6 of A2058 prevents hydrogen bonding of 2’OH group of the drug 
and also, more importantly, it adds bulky substituents onto the nucleotide causing 
steric hindrance for the binding of erythromycin. These studies implied that a 
Erythromycin 
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mutation of A2058 will disrupt the pattern of hydrogen bonding therefore impairing 
binding and rendering bacteria resistant.  
           
 
Figure 5 Interaction of Macrolides with Peptidyl Transferase Cavity: (a) Chemical 
structure diagram of the macrolides (erythromycin, clarithromycin and 
roxithromycin) showing the interactions of (colored arrows) of the reactive groups 
of the macrolides with the nucleotides of the peptidyl transferase cavity (colored). 
Colored arrows between the chemical moieties indicate that the two groups are 
less than 4.4 Å apart. (b) Secondary structure of peptidyl transferase ring of D. 
radiodurans showing the nucleotides involved in interaction with clindamycin 
(colored nucleotides). The colors in the secondary structure diagram match those 
of the chemical diagram. Nucleoties are numbered according to E. coli sequence. 
A2058 is indicated by an arrow (orange). Adapted from (Schlunzen et al. 2001) 
 
             
            Cladinose is suggested to be dispensable for binding and activity of 
erythromycin. The reactive groups of cladinose sugar are not involved in hydrogen-
bond interactions with the 23S rRNA. This is confirmed by structure and activity 
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relationship (SAR) studies that showed the 4’OH is dispensable for macrolide binding 
(Mao and Putterman 1969). 
           Although ribosomal proteins can affect the binding and action of ribosome-
targeted antibiotics, the primary target of antibiotics is the ribosomal RNA. One 
example where mutations in ribosomal proteins can lead to antibiotic resistance is in 
the loops of ribosomal proteins L4 and L22 that come close together in the wall of the 
peptide exit tunnel, very close to where MLSB antibiotics bind (Chittum and Champney 
1994). The mutations work in two different ways, either by preventing the drug binding 
(L4) or by neutralizing the effects of drug binding (L22) (Whittmann et al. 1973) . The 
ability of the ribosome to bind erythromycin is correlated with the width of the tunnel 
opening.  In an L4 mutant, the tunnel becomes substantially narrower, which does not 
bind erythromycin, making the opening slightly smaller than the erythromycin A 
molecule. In contrast, the L22 mutant ribosome had an opening twice the size of the 
macrolide and hence is not inhibited by the latter (Gabashvilli and Gregory 2001). 
These observations further support a simple steric hindrance mechanism as the 
mechanism of action of this drug by binding inside the tunnel and blocking it, hence 
preventing the growth of the polypeptide chain.  
           As mentioned earlier, post-transcriptional modification of 23S rRNA is one of the 
well characterized mechanisms for erythromycin resistance. This is brought about by a 
class of enzymes, erm (erythromycin resistance methylase) group of methyltransferases  
(Gaynor and Mankin 2003). They specifically catalyze N-6 mono or dimethylation of a 
highly conserved adenine residue at 2058 (E. coli numbering equivalent to A2085 in S. 
aureus) in the domain V of 23S rRNA. These methyl groups encroach on the MLSB 
binding site with in the peptide tunnel sterically hindering the binding of erythromycin. 
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This modification substantially reduces the binding of erythromycin to the exit tunnel that 
results in antibiotic resistance in erm carrying strains (Figure 6).  
 
       
 
Figure 6  A. Close up view of the spatial arrangement of nucleotides involved in 
macrolide binding in the exit tunnel as seen from the peptidyl transferase side. 
rRNA is shown as grey backbone, while nucleotides involved in interaction with 
macrolide antibiotics are colored in a space-fill representation. Proteins were 
removed for clarity. Color representations: Green 2057, Yellow 2611, Blue 2058, 
Cyan 2059, Purple 2609, B. same as panel A with two methyl groups on A2058 
(Orange). Adapted from (Garga-Ramos et al.  2002) 
 
           There are several rRNA erm methyltransferase isozymes conferring MLSB 
phenotype. Although the corresponding erm genes present a substantial DNA 
sequence diversity, products of all genes methylate the N6 amine of A2058 in the 
23S rRNA. All erm methyltransferases share a structurally homologous N-terminal 
catalytic domain that contains an S- adenosyl methionine (SAM) binding site that acts 
as the methyl group donor and a C-terminal RNA binding domain that holds the 
substrate. The methylases from erythromycin producers, Streptomyces erytherus 
(erm E) and Arthrobacter (erm F) are highly homologous (61%). The lowest levels of 
homology are between methylases from antibiotic producers (erm E, F) and non- 
producers (erm A, B, C and D) (18 to 24%) (Weisblum 1995). 
  A. B. 
CH3 
CH3 
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           Expression of erm methyltransferase can be induced by low concentrations of 
erythromycin. Erythromycin binds to ribosomes and the erythromycin-ribosome 
complex binds to the erm mRNA and changes its secondary structure. This facilitates 
expression of the erm gene in a process called translational attenuation (Grandi and 
Dubnau 1980, Vester et al. 1998). Inducibility is reversible and sensitivity to 
erythromycin is found after antibiotic removal.     
          Erm induction is well studied with the erm C gene expression. The inducible erm 
C cassette consists of two parts, the Erm gene whose expression is normally 
repressed due to sequestration of erm ribosome binding site in the secondary 
structure of mRNA and a constitutively expressed leader peptide cistron that precedes 
ermC (Dubnau 1985, Weisblum 1995) (Figure 7).  
           As shown in Fig 7A, in the uninduced ground state, segment 2 associates with 
segment 1 and segment 4 associates with segment 3. In this conformation, translation 
of ermC is initiated with a low efficiency because the first two codons of Erm C, AUG 
and AAU (fmet, Asn), as well as the ribosome binding site, are sequestered by the 
secondary structure. In this figure, Shine-Dalgarno sequences of the leader peptide 
(SD-1) and that of Erm cistron (SD-2) are also shown. Erythromycin induces the 
expression by favoring a translationally active conformation of ermC as shown in 
Figure 7B. When erythromycin binds to the ribosomes translating the 19 amino acid 
ermC leader peptide, the erythromycin-ribosome complex stalls around the 8th-9th 
codon of the leader peptide open reading frame. The stall of the ribosome triggers a 
conformational isomerization of the mRNA favoring the association of segments 2 and 
3. This, in turn, opens up the erm ribosome binding site, and culminates in an 
increased efficiency of ermC translation. Removal of erythromycin or maximal 
 24 
methylation of 23S rRNA results in an inactive conformation (Fig 7C). The 
conformational transition from 7B to 7A would also repress ermC, but energy would be 
required to dissociate stem 2:3. In contrast, the conformational transition from 7B to 
7C would not require additional energy and hence is favored. Because the ribosome 
pauses while it is translating the leader peptide, this type of induction is called 
”attenuation” and because the regulatory signal directly affects translation, this kind of 
mechanism of regulation is called ”translational attenuation”.  
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Figure 7 Conformational transitions of erm C leader sequence during induction 
(A) Conformation of erm C mRNA early during induction by erythromycin. The four 
major segments of erm C attenuator are paired as segments 1:2 and segments 3:4 
reflecting the temporal order of their synthesis. The ribosome is shown stalled during 
the addition of Ile-9 to the growing leader peptide. (B) Conformation of ermC leader 
mRNA during its fully induced state. (C) Inactive conformation of ermC mRNA. 
Adapted from (Weisblum 1995) 
Erythromycin-Ribosome 
complex stalled on the 
leader peptide 
Fully induced state 
Repressed state 
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          Because the stall on the leader ORF occurs only in the presence of the drug, the 
ribosome translating the leader peptide must bind the macrolide. On the other hand, 
for the translation of ermC cistron, ribosomes should be drug free. Thus the efficiency 
of erm induction depends critically on the macrolide concentration. Weisblum and 
colleagues have shown that induction of ermA expression occurred at 0.1 µM 
erythromycin and that resistant cells could be detected within 10 min of erythromycin 
addition (Weisblum et al 1985). 
         ErmE methyltransferase is one of the erm class enzymes that originates from the 
bacterium Saccharopolyspora erythraea that produces the macrolide antibiotic 
erythromycin (Skinner 1982). This gene must have evolved as a means of self 
defense. The recognition elements for the enzyme are contained within the domain V 
of 23S rRNA (Uchiyama 1985, Nielsen et al. 1999). It methylates protein free 23S 
rRNA in vitro, but 23S rRNA that is assembled into ribosomal subunits is no longer a 
substrate for the enzyme (Skinner 1983, Weisblum 1995). Thus, specific recognition of 
A2058 by the methyl transferase is directed by a motif in the 23S rRNA structure.  
         The sequence features of 23S rRNA needed for methylation are also known. The 
requirement for high enzyme fidelity in recognizing a single target A2058 amongst 
many other rRNA nucleotides suggests uniqueness and thus sequence complexity in 
 this motif structure. Nucleotides close to A2058 in the primary and secondary 
structures of the rRNA have been implicated in the Erm methyltransferase interaction 
(Kovalic et al. 1995). In bacteria, the conservation of the nucleotides at positions 2055 
and 2058-2061 is over 95%, but it is slightly lower for positions 2056 and 2057. 
However, the conservation of the secondary structure of this region is absolute, and 
the same irregular helix 73 structure is evident in all organisms. The ability of ermE 
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methyltransferase to modify 23S rRNA species from phylogenetically divergent 
bacterial species strongly suggests high level of conservation of secondary structure of 
the rRNA recognition motif.  
        Although 23S rRNA is the best studied in vitro substrate for erm 
methyltransferase, there is no free 23S rRNA existing in the cells. This is because as 
the ribosomal RNA is being synthesized it complexes with the ribosomal proteins to 
result in co-transcriptional assembly of 50S subunits. And, it was also found that fully 
assembled 50S subunits are not methylated by the enzyme (Champney 2003, 
Horinouchi 2006). A model for erythromycin inhibition predicts the accumulation of a 
stalled 50S precursor particle in erythromycin treated cells. Studies with E. coli have 
shown that a 50S precursor particle accumulates in erythromycin treated cells that 
co-sediments with the 30S subunits on the sucrose gradients (Figure 8).  
                    
 
Figure 8 Sucrose gradient profiles of S. aureus RN 1786 cells grown without (A) and 
with (B) erythromycin. Cells were lysed with lysostaphin and layered on 5-20% 
sucrose gradients.  Adapted from (Champney, Chittum, and Tober 2003)                                                                                                                                                                                                            
.  
                                                       
 
 
 
      30S + 
50S Precursor 
 
A. B. 
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        Relief from inhibition and continued particle synthesis can occur by precursor 
methylation, which reduces erythromycin binding to 50S ribosomes. Previous studies 
from our lab used a partially purified ermC methyltransferase and an S1 nuclease 
protection assay to identify the protected methylated nucleotides. The probe was a 
33-nucleotide DNA oligonucleotide complementary to S. aureus 23 rRNA sequences 
2061-2094 that includes the single ermC modified nucleotide A2085. This 
oligonucleotide was hybridized to 3H or 14C methyl labeled rRNA samples, and after 
S1 nuclease treatment radioactivity in the protected fragment was measured. In cells 
grown in the absence of erythromycin, ermC methyltransferase modified A2085 was 
protected only in the rRNA isolated from the 50S region of the gradient, whereas in 
erythromycin treated cells, significantly, this protected rRNA was found in the 30S 
region of the gradient where the 50S precursor is predicted to accumulate (Figure 9).  
       
Figure 9 ErmC methyltransferase labeling of ribosomal subunits. (A) Methylation of 
50S (□) and 30S(○) subunits from untreated cells. Methylation of 50S (■) and 30S(●) 
subunits from cells treated with erythromycin at 1µg/ml. (B) S1 nuclease protection 
assay on methylated sequences from 50S (□) and 30S (○) subunits from untreated 
cells. Nuclease protection assay on methylated sequences from 50S (■) and 30S (●) 
subunit gradient region from cells treated with erythromycin at 1 µg/ml. Adapted from 
(Champney, Chittum,  and Tober 2003) 
 
 
A. B. 
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         Based on these studies, a model has been proposed to explain the effects of 
erythromycin on ribosomes in wild-type and erm gene-containing cells (Figure 10) 
(Champney 2003). In cells lacking an erm gene, 50S subunit formation proceeds 
through the normal assembly sequence. In wild type organisms, erythromycin stalls 
50S particle formation and the stalled subunit is degraded by the ribonucleases in the 
cell.  In cells with an inducible erm gene erythromycin will also stall assembly of the 
nascent subunit. However, in this case the stalled precursor particle is a substrate for 
the induced erm methyltransferase enzyme. Methylation of 23S rRNA in the precursor 
particle relieves the assembly inhibition, permitting synthesis of methylated particles 
that are resistant to the inhibitory effects of the antibiotic. This assembly sequence 
explains why the mature 50S subunits are not methyltransferase substrates. Since 
cells do not contain protein free 23S rRNA and it was observed that mature 50S 
subunits are not substrates for the enzyme, the in vivo substrate for the enzyme is the 
50S precursor particle that accumulates in the 30S region of the drug treated cells. 
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    Figure 10 Model for the 50S subunit formation in S. aureus cells. 
   (A) Subunit formation in untreated control cells.  
   (B) Erythromycin-stimulated inhibition of 50S formation in antibiotic-sensitive cells.  
   (C) Reversal of erythromycin inhibition of subunit formation by erm  
         methyltransferase in antibiotic-induced cells indicating competition between the  
         two. (E=Erythromycin). Adapted from (Champney, Chittum, and Tober 2003) 
            
            
Competition 
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          The chief objectives of the current studies were to establish the 50S ribosomal 
precursor particle as the true in vivo substrate for the ermE methyltransferase enzyme 
and to characterize the ribosomal RNA and protein content of this precursor particle. 
Previous studies from our laboratory with ermC methyltransferase have shown that a 
50S ribosomal subunit precursor particle that accumulates in the erythromycin induced 
cells acts as an important substrate for the enzyme (Champney et al. 2003). 
Observations from the S1 nuclease protection assay also corroborated a 50S 
precursor particle as a substrate for erm methyltransferase. 
          In the same studies when ribosomal subunits were used as enzyme substrates, 
it was found that 50S subunits were not substrates. Collectively, these results suggest 
that the 23S rRNA that is already assembled into 50S subunits is not methylated by 
the enzyme while the 23 rRNA in the 30S region of the erythromycin treated cells is a 
substrate. These observations further substantiate 50S precursor particle as the true in 
vivo substrate for the erm methyltransferase.  
          For the current studies, Staphylococcus aureus wild type strain RN 1786 that 
does not have an inducible erm gene was used (Koepsel 1985). It is hypothesized that 
the in vivo substrate for ermE methyltransferase is the 50S ribosomal precursor 
particle that sediments along with the 30S subunit region on the sucrose gradients. An 
additional hypothesis is that this precursor particle can bind erythromycin in vitro and 
that it consists of a subset of the 50S ribosomal proteins that are important for 
erythromycin binding and ermE methylation.  
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         Another focal point of these studies was to examine the competition between 
erythromycin and ermE methyltransferase binding to the 50S precursor particle. In the 
cells with inducible erm gene, erythromycin induces the expression of erm 
methyltransferase that in turn methylates the stalled 50S assembly intermediate. This 
scenario suggests a competition between the enzyme and the drug for the same 
substrate, the 50S precursor particle. So, a further hypothesis was that, there would be 
a competition between MLSB antibiotics and ermE methyltransferase for the 50S 
precursor particle in a concentration dependent manner.  
             An important factor here would be the stoichiometry of erythromycin binding to 
the ribosomes versus the ermE catalysis. As mentioned earlier, the predicted 
stoichiometry of erythromycin binding to the precursor particle is 1:1 where every 
single stalled precursor molecule would have one drug molecule bound. However, a 
single enzyme molecule can repeat the catalysis cycles to methylate more than one 
50S precursor rendering them resistant. Hence, in the presence of erm, higher 
erythromycin concentrations would be needed to compete with the enzyme and to 
prevent the build up of methylated ribosomes. These predicted in vivo conditions 
indicate that in the presence of these two competing agents, the association constant 
(Kd) of the ribosome for either of them would determine whether a bacterial ribosome 
becomes resistant or not. This, in turn, would critically depend on their concentration. 
Understanding the competition phenomenon between the drug and the enzyme would 
be a significant step towards determining effective drug concentrations in organisms 
carrying resistance determinants. 
         One more vital goal of the current project was to characterize the ribosomal RNA 
and protein contents of the 50S precursor particle that accumulates in the presence of 
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erythromycin. Ribosomal RNA of the 50S precursor was identified by slot blot 
hybridization. As another part of these studies, the proportion of the 50S precursor 
particle in cells treated with increasing concentrations of erythromycin was also 
examined. Because it was previously shown that erythromycin binds to the ribosomes 
in 1:1 ratio, it would be logical to predict that with an increase in the drug concentration 
and a concomitant increase in 50S assembly stalling, the accumulation of the 50S 
precursor particle would also increase.  
           Protein characterization of the 50S precursor particle was performed by two-
dimensional polyacrylamide gel electrophoresis and mass spectrometry.  Previous 
studies from our laboratory with E. coli cells have shown that the 50S precursor can 
bind erythromycin in 1:1 ratio and that it contains 18 of the total 35 proteins of the 50S 
subunit (Usary and Champney 2001). 2D gel electrophoresis with the acidic first 
dimension and basic second dimension proved to be a successful technique for the 
otherwise hard to separate ribosomal proteins. But, unfortunately, unlike in E. coli, the 
ribosomal proteins of S. aureus were not well characterized. Hence to identify S. 
aureus ribosomal proteins on the 2D gels, molecular weights of the ribosomal proteins 
predicted from its genome sequence were used as an index (Holden et al. 2004). 
          Mass spectrometry is a powerful tool in protein analysis. Matrix-assisted laser 
desorption ionization (MALDI) (Karas et al 1987)  time-of-flight (TOF) (Brown and 
Lennon 1995, Whittal and Li 1995), and electrospray (Fenn and Whitehouse 1989) 
technologies can be used to precisely detect changes in proteins and peptides. These 
techniques involve ionization of molecules into products that can be detected. The 
mass-to-charge ratio of gas phase ions can then be correlated with the molecular 
structure of the initial species. In MALDI, gas phase ions are generated by desorption  
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ionization of the molecule of interest from a layer of crystals formed from volatile matrix 
molecules. This technique has been used to detect all 56 ribosomal proteins of E. coli 
with posttranslational modifications and to detect alterations responsible for antibiotic 
resistance ( Wilcox and Pearson 2001).  In the current studies, MALDI-TOF mass 
spectrometry was used to identify the 50S proteins in the 50S precursor region of the 
erythromycin treated cells. The sensitivity of this method should ensure detection of all 
proteins.  
        Hydrophobic interaction chromatography (HIC) was used previously to purify 
bacterial ribosomes (Kirillov and Semenkov 1978, Ramakrishnan et al.1986, 
Saruyama 1986). One other aim of the current project was to evaluate HIC as a 
possible method to separate the 50S precursor from the 30S + 50S precursor mixture. 
Methylation of purified 50S precursor from the 30S, 50S precursor mixture would 
authenticate the former as the true in vivo substrate for erm methyltransferase. The 
principle of HIC is the difference in the hydrophobic interaction of the ribosomal 
subunits with the hydrophobic column material in low concentrations of Mg2+ ions. 
Because the 50S precursor particle is expected to have a different hydrophobicity than 
the 30S subunits, it should be possible to use HIC as a potential method for 50S 
precursor purification. 
         These studies will provide more information about the true nature of the 
substrate for the ermE methyltransferase, which is an important enzyme resulting in  
erythromycin resistance. Significantly, these studies will also focus on the competition 
between erythromycin and ermE methyltransferase for the 50S precursor particle that 
could potentially open up new targets for antibiotics. With the rapid emergence of 
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antibiotic resistant bacteria, it is essential to seek new antibiotic targets such as the 
50S assembly intermediate. 
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CHAPTER 2 
MATERIALS AND METHODS 
Materials 
 
             Erythromycin, lincomycin, virginiamycin S, chloramphenicol, lysostaphin, 
 DNAase I, RNA guard, Tris base, Tris-HCl, phenylmethylsulfonylfluoride (PMSF), Hepes, 
β-mercaptoethanol, Isopropyl Thio-Galactoside (IPTG), imidazole, and Octyl-Sepharose 
6B were purchased from Sigma Chemical Corporation. Tryptic Soy Broth, tryptone, yeast 
extract, sucrose, urea, ammonium chloride, magnesium chloride, magnesium acetate, 
ammonium sulfate, glycine, glacial acetic acid, methanol, trichloro-acetic acid, phenol, 
chloroform, sodium lauryl sulfate (SDS), 2-propanol, formaldehyde, bovine serum 
albumin, sodium hydroxide, sodium chloride, potassium hydrogen phosphate 
(monobasic), potassium hydrogen phosphate (dibasic), sodium citrate, scintisafe gel 
scintillation fluid, Fuji-medical X-ray film, Kodak Film developer, and fixer were purchased 
from Fisher Scientific. Nytran SPC nylon transfer membranes for slot blot hybridizations 
were purchased from Scheicher & Schuell. Nitrocellulose membrane for Western blotting 
was purchased from Hoefer. SDS-PAGE low molecular range molecular weight standards 
and acrylamide were purchased from Biorad Inc. PCR primers were obtained from Life 
Technologies. The GF/A glass fiber filters and blotting paper were purchased from 
Whatman International. Millipore filters were purchased from Millipore Inc. 35S-methionine 
(TRANS35S-LABEL 1175 Ci/mmol) was purchased from MP Biomedical.  14C Erythromycin 
(55 mCi/mmol) and Adenosyl-L-Methionine, S-(Methyl-3H) (9.8 Ci/mmol) were purchased 
from PerkinElmer Lifesciences Inc, Boston, MA. Mouse anti-6His monoclonal antibody 
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(BD Biosciences) was a generous gift from Dr. Antonio Rusinol. Anti-Mouse IgG HRP 
conjugate was bought from Promega Corp, Madison.  
Cricket Graph III software (Computer Associates) was used to construct graphs.   
Curve fitting was also performed using Cricket Graph software.  Curve fits were chosen 
according to best fit. 
Labeling and Detection Kits: 
1.  Commassie Plus-Better Bradford Assay kit was purchased from Pierce Biotechnology. 
2.  Mirus Label-IT® biotin labeling kit was purchased from Fischer Scientific. 
3.  The North2South® chemiluminescent nucleic acid hybridization and detection kit was  
     purchased from Pierce Chemical Corp. Washing, pre-hybridization solution, and  
     background quencher were purchased from Molecular Research Center, Inc.   
4.  HIS-Select TM HC Nickel affinity gel was purchased from Sigma Chemical Co. 
 
Bacterial Growth Media 
  1. Tryptic Soy Broth: 30 gm of Tryptic Soy Broth was dissolved in 1 L water and sterilized    
      by autoclaving. 
2. Luria Broth: 10 gm tryptone, 10 gm NaCl, and 5 gm of yeast extract were dissolved in 
water and pH was adjusted to 7.5 with 1.5 M NaOH and diluted up to 1 L. 
 3.  A salts: 52.5 gm K2HPO4, 22.5 gm KH2PO4, 5.0 gm (NH4)2 SO4, 2.5 gm Sodium citrate,  
      1 ml 20% MgSO4 and made up to 1 L. (Miller 1972) 
  4. Staphylococcus Labeling Media (SLM): 1X A Salts supplemented with 10 gm/L NaCl,  
      0.2 gm/L Mg2SO4, 5 gm/L glucose, 2 gm/L desiccated beef extract (Difco), and 25 mg/L  
      each of cysteine, tyrosine, and tryptophan. (Champney et al. 2003) 
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BUFFERS 
1.  SAS: 10 mM Tris-HCl, pH 8.0, 100 µM MgCl2, 50 mM NH4Cl 
2.  R Buffer: 10 mM Tris-HCl, pH 7.6,10 mM MgCl2, 50 mM NH4Cl,  
     2.8 mM β-mercaptoethanol 
3.  Wash Buffer: 25 mM Tris-HCl, pH 7.8, 60 mM KCl, 20 mM Magnesium acetate 
4.  Binding Buffer: 50 mM Tris-HCl, pH 7.8,80 mM KCl, 16 mM Magnesium acetate 
5.  Equilibration buffer: 50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, 
    10 mM imidazole. 
6.  High salt wash buffer for ermE methyltransferase:  20 mM Tris-HCl, pH 8.0, 10 mM  
     magnesium acetate, 6 mM β-mercaptoethanol, 1 M NH4Cl, 10% glycerol 
7.  2X Assay buffer : 100 mM Tris-HCl, pH 8.0, 8.0 mM MgCl2, 80 mM KCl, 20 mM DTT,  
     12 mM NaCN 
8.  TE: 10 mM Tris-HCl, pH 7.8, 1 mM EDTA 
 
Twelve Percent Polyacrylamide Gel Electrophoresis  
1.  Resolving gel solution: 1.8 ml 40% acrylamide-bisacrylmide, 1.5 ml of 1.5 M 
     Tris –HCl, pH 8.8, 2.62 ml H2O, 60 µl of 10% SDS, 6 µl TEMED and 60 µl 10% APS.  
2.  Stacking gel solution: 0.5 ml 40% acrylamide-bisacrylmide, 0.38 ml 1.0 M Tris-HCl  
     pH 6.8, 2.1 ml H2O, 30 µl 10% SDS, 3 µl of TEMED, 30 µl 10% APS. 
3.  10 X SDS Running buffer: 30.3 gm Tris base, 144 gm glycine, 10 gm SDS in 1 L final  
      volume 
4.  2X SDS sample buffer: 125 mM Tris HCl, pH 6.8, 4% SDS, 20% Glycerol, 0.02%  
     bromophenol blue                                                  
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Two-Dimensional Gel Electrophoresis 
2D sample buffer: 7.69 M Urea, 10 mM Bis-Tris, 0.6% glacial acetic acid, 144 mM  
    β- mercaptoethanol. 
 
1st Dimension: 
1.  Separating Gel Solution: 4% acrylamide, 0.132% bis-acrylamide, 8 M urea,  
     40 mM bis-tris, 0.45% acetic acid, pH 5.5. 
2.  Upper buffer: 2.5 ml 1 M Bis-Tris, 900 µl glacial acetic acid, make up to 250 ml with  
     dH2O, pH 3.8. 
3.  Lower buffer: 2.5 ml 1 M Bis-Tris, 100 µl glacial acetic acid, make up to 250 ml with  
      dH2O, pH 6.0. 1 ml of separating gel solution pH 5.5 was polymerized in the tube with  
      1 µl TEMED and 3 µl 10% ammonium per sulfate. 
4.  Dialysis buffer: 40 mM Bis-Tris, pH 6.0, 6.0 M urea, 1% SDS 
 
SDS 2nd Dimension:  
5.  Upper buffer: 50 mM Bis-Tris MES, pH 6.5, 0.2% SDS 
6.  Lower buffer: 20 mM Bis-Tris acetic acid, pH 6.75 
7.  Resolving gel solution: 12.5 % Acrylamide, 0.25% Bis Acrylamide, 6 M urea, 0.1 M  
     Bis-Tris acetic acid, pH 6.75. Resolving Gel solution was polymerized with 30 µl TEMED  
     and 300 µl of  10% APS. 
8.  Stacking gel solution: 4% Acrylamide, 0.066% Bis Acrylamide, 6 M urea, 0.2% SDS,  
     0.04 M Bis-Tris acetic acid, pH 6.0. Stacking gel solution was polymerized with 20 µl of  
    TEMED and 200 µl of 10% APS.  
9.  Sample buffer: 0.04 M Bis-Tris acetic acid pH 6.0, 8M urea, 1% SDS,  
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   1% β-mercaptoethanol. 
 
Slot-Blot Hybridization 
1.  Hybridization buffer: 50% formamide, 5X SSC, 0.1% Sarkosyl, 0.02% SDS, and  
    200 µg/ml BSA 
 
Hydrophobic Interaction Chromatography 
1.  Buffer C:  10 mM magnesium acetate, 20 mM Hepes, pH 7.5.  
 2.  Elution Buffer: Buffer C was mixed with (NH4)2S04 to give a final concentration of 0.1 M,  
     0.25 M, 0.5 M, 0.75 M, 1.0 M, 1.25 M or 1.5 M. 
 
 
Western Blotting 
1. Transfer Buffer: 25 mM Tris, 192 mM glycine, 20% Methanol, 0.025% SDS 
2. TBST: 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20 
                                       
                                                        Bacterial Strains 
1. Staphylococcus aureus strain RN 1786 was used for these current studies, provided by  
    J. Sutcliffe of Pfizer (Koepsel et al. 1985). 
2. E.coli DH1 cells transformed with plasmid perm 60, containing a cloned ermE gene  
    encoding for ermE methyltransferase enzyme with a C-terminal His tag was a generous  
    gift from Dr. S.R. Douthwaite (Vester et al. 1998). 
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Methods 
                                            
Effect of Erythromycin on Cell Growth and Cell Viability 
            Erythromycin was dissolved in methanol at 10 mg/ml. RN 1786 cells were grown 
in TSB at 370C in the absence and presence of 1 µg/ml erythromycin. In some 
experiments, erythromycin was used at 0.1, 0.25, 0.5, 1.0 or 2.0 µg/ml concentrations. 
Cell growth was initiated by adding 1 ml of overnight culture to 20 ml TSB growth media. 
Cell growth was measured by following the increase in cell density in a Klett - Summerson 
colorimeter. The antibiotic was added at a Klett of 20 and cell growth was monitored over 
a period of two cell doublings. At this point 10 µl of the culture was added to 990 µl of 1x 
A salts, a serial dilution was performed to achieve a final dilution of 10-5 and 10 µl was 
plated on TSB agar plates (Jett and Hatter 1997). Plates were incubated at 370C for 24-
48 hrs. The numbers of colonies formed were counted from control and drug treated cells 
to determine the effect of antibiotic on the total viable cell number.  
  
Effect of Erythromycin on Protein Synthesis 
         Twenty ml cell cultures were grown as described above.  After 2 cell doublings in 
the presence or absence of antibiotic, 35S-methionine Trans label was added to the 
culture at a concentration of 1 µCi/ml.  Three samples of 0.2 ml were removed at 5 minute 
intervals after the addition of the 35S-methionine. Proteins were precipitated in 10% TCA 
and 0.2% BSA and were collected on Whatman GF/A glass fiber filters. The filters were 
washed with 10% TCA and 97% ethanol to ensure removal of free 35S-methionine.  Filters 
were air dried under a heat lamp and placed in vials with 3 ml Scintisafe Gel and 
radioactivity was measured by liquid scintillation counting. 
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Cell Lysis and Ribosomal Subunit Isolation 
              Cell lysis for ribosomal subunit and ribosomal RNA isolations were performed as 
described previously (Champney and Tober 1998). Cell pellets from 500 ml cultures were 
resuspended in 1 ml of SAS buffer, and 40 µg/ml lysostaphin, 0.1 M PMSF were added 
and lysis was carried out by incubating at 370C for 30 min. After incubation, cells were 
frozen for 5 min at -700C and thawed at room temperature. Freeze/thaw cycle was 
repeated 3 times. DNA in the samples was digested by adding 5 µg/ml DNAase I and 
incubating at room temperature for 10 min. Cell lysates were centrifuged at 4200 Xg for 
10 min to separate the cell debris. Ribosomal subunits were isolated by centrifugation on 
5-20% linear sucrose gradients. Gradients were made using a Buchler gradient maker 
and 18 ml each of 5% and 20% sucrose in SAS buffer. The clear lysate supernatant 
obtained above was layered on the prepared gradients and was placed in a SW27 
swinging bucket rotor and centrifuged in a Beckman LE80K Ultracentrifuge at 42000 Xg 
for 18 hours. An ISCO Model UA-5 absorbance monitor was used to measure and record 
the absorbance at 254 nm of the gradients as they were pumped through.  The 30S 
subunits were collected first followed by the 50S subunits. Subunits were precipitated by 
increasing the concentration of MgCl2 to 1 mM and by adding 2 volumes of ice cold 
absolute ethanol. Ribosomal RNA was isolated from the subunits by phenol extraction. 
For this, an equal volume of Tris saturated phenol was added to the subunits, mixed by 
flipping the tube gently, kept on ice for 10 min and centrifuged in a microfuge at 10,000 
rpm for 10 min. The aqueous supernatant was carefully recovered and equal volume of 
chloroform: isoamylalcohol (24:1) mixture was added, mixed by flipping gently, kept on ice 
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for 10 min and centrifuged at 10,000 rpm for 10 min. To the supernatant 2 volumes of ice 
cold ethanol was added and rRNA was precipitated overnight at -200C. 
    
Purification of ermE Methyltransferase 
              An overnight culture of E. coli DH1 with perm60 was started by inoculating 5 ml 
of LB medium containing 100 µg/ml ampicillin with 0.5 ml glycerol stock an by adding. The 
next day, 500 ml of LB medium with 100 µg/ml ampicillin was inoculated with 1 ml 
overnight culture. At an optical density at 600 nm of 0.6, ermE expression was induced 
with 1 mM IPTG and cells were allowed to grow for another 3.5 hrs. Cells were harvested 
by centrifugation at 4200X g for 30 min followed by washing with 5 ml of R buffer and 
were frozen at -800C. Cell lysis was achieved by adding 100 µg/ml fresh lysozyme and 
2.5 mM PMSF and incubating at 370C for 20 min until the solution turned turbid. The 
lysate was then subjected to 3 freeze thaw cycles, 5 U/ml of DNAase I was added and 
incubated at room temperature for 5-10 min until the turbidity cleared. Cell debris was 
cleared by centrifugation at 4200 X g for 10 min. The supernatant containing the 
ribosomes was pelleted down by spinning at 121000 X g for 3.5 hrs in Ti 50 rotor. ermE 
methyltransferase was obtained associated with the ribosomes. The enzyme was then 
washed from the ribosomes by suspending the pellet obtained in the previous step with 
high salt wash buffer containing 1 M NH4Cl overnight.  Crude extract of the enzyme was 
obtained by centrifugation at 121,000 X g for 3.5 hrs in Ti 50 rotor. Enzyme extract was 
then diluted to bring the salt concentration down 0.25 M.  
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Ni-affinity Chromatography 
            ermE methyltransferase with a C-terminal His- tag was further purified on HIS-
Select TM HC Nickel affinity gel. The affinity gel was first washed with 1 to 2 volumes of 
deionized water to remove ethanol and then equilibrated with 5 volumes of equilibration 
buffer. Crude enzyme was mixed with the affinity gel and shaken on ice for 1-2 hrs. 
Unbound proteins were washed off the gel by equilibration buffer and the enzyme was 
eluted with elution buffer containing 250 mM imidazole. The eluate fractions were 
dialyzed into the R buffer with 10% glycerol to remove salts. Integrity of the enzyme was 
then assessed by Western blot using anti-6His Mouse monoclonal antibody. 
                                                      
Western Blotting 
        Integrity of ermE methyltransferase prepared above was determined by Western 
blotting using anti-6His mouse monoclonal antibody. Protein quantitation of the wash and 
elution fractions the Ni-affinity column and the crude enzyme fraction from the high salt 
wash of the ribosomes was done by Bradford reagent method in the test tube format 
(Commassie Plus-Better Bradford Assay, Pierce Biotechnology). For Bradford assay, a 
standard curve was obtained with BSA in the concentration range from 20 to 200 µg. 
Simultaneously, 100 µl of enzyme fractions were diluted to 1 ml with dH2O and 1 ml of 
Commassie Plus reagent was added.  Samples were allowed to stand at room 
temperature for 20 min and absorbance was measured at 595 nm. Concentration of 
protein was deduced form the BSA standard curve. Twenty µg of each sample was 
concentrated by precipitation with 5 volumes acetone overnight. Samples were 
centrifuged at 4200 X g for 30 min and the protein pellets were air dried. Dried samples 
were dissolved in 10 µl of water and an equal volume of 2X SDS sample buffer was 
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added. Samples were denatured by heating at 950C for 5 min and snap cooled on ice and 
briefly spun down. Samples were then subjected to 12% PAGE. 
 
Twenty Percent SDS- Polyacrylamide Gel Electrophoresis 
            Twenty percent SDS-PAGE was carried out in the Biorad minigel apparatus. 
Electrophoresis was carried out in 1X SDS Running buffer at 50 V until the samples 
migrated into the resolving gel and then at 100 V until the bromophenol blue dye front 
migrated to the bottom of the gel. 
             At the end of the electrophoresis, the gel was pre equilibrated for 15 min in 
transfer buffer. A nitrocellulose membrane (pore size 0.45 µm, Hoefer) cut to the size of 
the gel, filter pads, and Whatman number 1 filter papers cut to the size of the filter pads 
were also soaked in the transfer buffer for 15 min.  Transfer cassette was assembled 
according to the manufacturer’s instructions of Biorad Mini Trans-Blot Cell. The gel 
sandwich was prepared with the grey side of the cassette down, followed on top by the 
pre-wetted filter pads and the filter paper. The pre-equilibrated gel was placed on the filter 
paper and the nitrocellulose membrane was placed on top of the gel. The cassette 
assembly was completed by placing the last filter paper and the filter pad. Any air bubbles 
trapped in the cassette were carefully removed by gently rolling a glass rod.  Western 
transfer of proteins was carried by electro transfer in the Biorad Mini Trans-Blot Cell at 20 
V overnight on a magnetic stirrer in the cold room at 40C. After the transfer, the 
nitrocellulose membrane was carefully removed from the cassette and further processed 
for the protein detection. All further operations were carried out at room temperature with 
gentle shaking. 
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1. Blocking: The membrane was blocked in TBST with 5% dry milk powder for 1 hr. 
2. Primary antibody: Anti-6 His Mouse Monoclonal antibody (BD Biosciences) was     
diluted to 0.1 µg /ml with TBST with 5% milk and incubated with the membrane for 
           1 hr. Then the membrane was washed in TBST 3 times for 10 min each.  
      3.  Secondary antibody: Anti Mouse IgG-HRP conjugate (Promega) was diluted 1 µl to  
          10 ml in TBST with 5% milk and added to the membrane, incubated for 1 hr.  
   Washes were carried out with TBST 6 times for 5 min each.   
   4. Detection: HRP substrate was made by mixing 1 ml peroxide and 1 ml luminal  
       enhancer solutions (Pierce) just before use. They were added on the membrane and  
       incubated for 5 min and decanted. Proteins were visualized by exposing the  
       membrane to an X-ray film immediately. The exposure time was adjusted from 2 sec  
       to 45 sec depending on the signal strength. 
 
ermE Methyltransferase Activity Assay 
           ermE Methyltransferase activity assays were performed in a total volume of 100 µl 
containing, 20 pmols of the respective substrate (23S rRNA, 30S subunits, 50S precursor 
particle, 50S subunits, or 16S rRNA), 3 µCi of 3H –S-adenosyl methionine, 30 pmols of 
the purified ermE methyltransferase enzyme, 50 µl of 2X assay buffer. After incubation at 
370C for 20 min, reactions were stopped by adding 100 µl of TE buffer. 3H Methylated 
RNA samples were extracted once with phenol and once with chloroform, then 
precipitated with 10% TCA. Samples were washed on GF/A glass fiber filters with 10% 
TCA and ethanol to wash off the unincorporated  3H-S-adenosyl methionine. Filters were   
placed in vials with 3 ml Scintisafe Gel and 3H methyl labeled RNA was counted by liquid 
scintillation counting.                                           
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MLS Inhibition of ermE Methylation 
                Erythromycin, lincosamide, and virginiamycin S were tested as inhibitors of 
ermE methylation. MLS drugs were diluted in 2X methylation assay buffer. To study 
inhibition by MLS drugs, ermE methyltransferase activity assay was carried out as 
described above but in the presence of a range of concentrations of MLS drugs from  
0 to10 nmols. At the end of the incubation, reactions were stopped and samples were 
processed as described above for the methyltransferase assay.  
 
14C Erythromycin Binding Studies 
                 14C Erythromycin binding reactions were carried out in a final volume of 200 µl 
containing, 50 µl of binding buffer, 400 pmols of 14C erythromycin, and 0, 20, 30, 40, and 
80 pmols of one of the substrates (50S ribosomal subunits, 50S precursor particle, or 30S 
subunits). Samples were incubated at 370C for 20 min and the reactions were stopped by 
adding 2 ml binding buffer. Unbound 14C erythromycin was washed off on Millipore 
membrane filters with 15 ml wash buffer and the bound 14C erythromycin was counted by 
liquid scintillation counting.                
                        
ermE Methyltransferase and Erythromycin Competition Experiments 
           Competition experiments were carried out with fixed concentration of erythromycin 
and a range of concentrations of ermE methyltransferase. One set of assay reactions was 
set up with the concentration of erythromycin kept constant at 80 µM and 0, 0.32, 0.64, 
0.96, 1.2, and 1.5 µM of ermE methyltransferase, 3 µCi of 3H-S-adenosyl methionine, 50 
µl of 2X assay buffer in a final volume of 125 µl. Another set of competition reactions was 
set up similarly but with 14C erythromycin and unlabeled S-adenosyl methionine instead of 
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the unlabeled erythromycin and 3H S-adenosyl methionine used in the first set. Reactions 
were incubated at 370C for 20 min and stopped by adding 100 µl of TE buffer at the end 
of the incubation period. In the first set of reactions, 3H methyl RNA was extracted and 
counted as described for ermE methyltransferase assay. In the second set, bound 14C 
erythromycin was quantified as described in 14C erythromycin binding studies. Results 
were plotted on Cricket graph depicting either increase in 3H methyl RNA formed or 
decrease in 14C erythromycin bound as a function of ermE methyltransferase 
concentration. 
 
Two-Dimensional Polyacryamide Gel Electrophoresis 
           Ribosomal proteins were isolated from twenty A260 units of 30S and 50S 
subunits of Staphylococcus aureus RN 1786 cells by acetic acid extraction and 
concentrated by precipitation with 5 volumes of acetone (Madzar et al.1979). After 
drying the sample, samples were suspended in 75 µl of 2D sample buffer pH 4.2 and 
gels were run as described. 
First Dimension Gel Electrophoresis  
The acidic first dimension gel electrophoresis was performed in glass tubes measuring 
0.2 x 10 cm. Electrophoresis was carried out with cathode on top at 60V for 1 hr and 
then at 150V for 5 hrs. 
Dialysis: First dimension gel was extruded from the glass tube and dialyzed for 1 hr in 
SDS- Dialysis buffer. 
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SDS- Second Dimension Gel Electrophoresis 
Gels were cast in Hoefer SE500 Gel slab apparatus. An agarose plug was made with 3 
µg of Low Molecular weight standards (95 Kd- 14 Kd, Biorad Inc).  
Electrophoresis was carried out with anode on top at 50 V for 1 hr and at 100 V for 5 
hrs. The gel was stained with Commassie Brilliant Blue R 250 to detect protein spots. 
                                                            
MALDI-TOF Mass Spectrometry 
          Ribosomal protein samples were prepared from 30S and 50S subunits and 50S 
precursor region as described for the two-dimensional gel electrophoresis. After 
acetone precipitation, samples were dried in microfuge tubes and were analyzed by 
MALDI-TOF mass spectrometry at Columbia University Core Facility, New York.  The 
Mass Spectrometer used was an Applied Biosystems Voyager DE Pro.  Sample 
preparation and analysis was done as described by Wilcox et al. Briefly, samples were 
resuspended in 1% TFA to give 25 mg/ml.  A saturated solution of sinapinic acid was 
prepared in a solution containing 30% acetonitrile and 0.1% TFA for the matrix solution. 
The sample for MALDI-TOF mass spectrometric analysis was then prepared by diluting 
1.0 µl of protein solution to 10 µl with matrix solution and was spotted onto a flat, 
stainless steel target from PerSeptive Biosystems. MALDI-TOF data were collected on 
a PerSeptive Voyager Elite MALDI-TOF instrument with delayed extraction in positive-
ion linear mode. Myoglobin was used to internally calibrate each spectrum.  
              A minimum of 150 µg of each sample was used for a single analysis. Resulting 
MALDI spectrum was analyzed and peaks corresponding with the molecular weights 
predicted from the S. aureus genome were identified.  50S proteins in the 30S + 50S 
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precursor mixture region were identified by comparing with control 30S and 50S 
proteins of S. aureus.                     
                                    
Slot-Blot Hybridization 
           A 101 bp biotinylated DNA oligonucleotide from S. aureus 23S ribosomal RNA 
sequence 2002-2103 was used as a probe that was complementary to a region of 23S 
rRNA that spans the erm methylation site of A2085. The probe was prepared by PCR 
amplification using the primers, F-GTAACGATTTGGGCACTGT and  
R-AAGCTCCACGGGTCT from Life Technologies. The PCR reaction mixture contained 
45 µl of PCR Supermix High Fidelity reagent (Gibco BRL), 6 ng (1 µl) of Staphylococcus 
aureus RN 1786 total DNA, 1 µl (10 pmols) each of the forward and reverse primers, 
and 2 µl of sterile water. Samples were amplified for 35 cycles under the following 
conditions: denaturation at 940C for 30 s, annealing at 570C for 30 s, and extension at 
720C for 30 s. The PCR products were purified by extraction with equal volume of 
phenol:chloroform  and precipitated with 2 volumes of ethanol. The pellets were dried at 
370C for 15 min and then resuspended in 30 µl of sterile water.  The purified 50S 
precursor probe was labeled with biotin using Label-IT biotin labeling kit (Mirus Inc) 
following the manufacturer’s instructions. Briefly, 50 µl of labeling reaction was set up 
with 5 µl each of 10X labeling buffer A, 5 µg of 101 bp DNA oligonucleotide probe and 
Label IT reagent and 35 µl of sterile water. The reaction mixture was incubated at 370C 
for 2 hrs. The biotin labeled probe was then purified on the microspin column provided 
with the kit.  Just before use, the probe was denatured by 0.1 volume of denaturation 
buffer D1 (Mirus Inc.) by incubating at room temperature for 5 min followed by chilling 
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on ice for 5 min. The probe was then neutralized by 0.1 volume of neutralization buffer 
N1 (Mirus Inc.) and incubated at room temperature for another 5 min. 
          Ribosomal RNA was prepared from RN 1786 with phenol and chloroform 
extraction as described above. 23S rRNA (positive control) and 50S precursor region of 
the gradient were used in amounts 0.5, 1.0, 1.5, 2.0 and 5.0 µg of and the and 2 µg of 
16S rRNA (negative control) were spotted on a nylon membrane (Nytran, Schleicher & 
Schuell) using the slot blot apparatus. RNA was cross linked to the membrane in a UV 
Crosslinker oven (FisherBiotech). The membrane was pre-hybridized at 420C for 30 min 
in 15 ml of 1X Prehybridization solution. The membrane was hybridized at 420C 
overnight in 7 ml of hybridization buffer with 1X background quencher (MRC Inc.) and 4 
pmols of denatured 50S precursor probe prepared as described above. Following 
hybridization, the membrane was washed and the biotinylated probe was detected 
using the North2South chemiluminescent hybridization kit (Pierce Chemical Co.) 
according to the manufacturer’s instructions.  
         A standard curve was obtained for the 23S rRNA based on the signal intensity of 
each spot quantified by AlfaImagerTM 2200 Documentation & Analysis System (Alfa 
Innotech Corp. San Leandro, California). The images on the slot blot containing the 50S 
precursor samples were also scanned to obtain Integration Density Values (IDV) that 
are direct measures of the signal intensity. From these IDVs, the amount of 23S rRNA 
present in 2 µg of each 30S+ 50S precursor mixture sample was calculated from the 
23S standard curve. This yielded the percentage of 23S rRNA in each sample, which is 
a direct measure of percentage of 50S precursor particle in the 30S region of 
erythromycin treated cells.      
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Hydrophobic Interaction Chromatography 
          The 50S precursor particle was separated from the 30S + 50S precursor mixture 
by hydrophobic interaction chromatography. Octyl-Sepharose 6B was used as the 
hydrophobic matrix and was poured in a 15 x 1 cm column (Pharmacia Fine Chemicals, 
Uppsala, Sweden). The column was equilibrated with buffer C with a stepwise increase 
in ammonium sulfate concentration from 0.1 M to 1.5 M. Equilibration was carried out 
until the pH of buffer eluting from the column was the same as that of the equilibration 
buffer applied on top of the column. 35S-Methionine labeled ribosomal subunits were 
applied on the column and eluted with a stepwise reverse gradient of ammonium sulfate 
from 1.5 M to 0.1 M. Fractions were collected at each salt concentration (1.5 M, 1.25 M, 
1.0 M, 0.75 M, 0.5 M, 0.25 M, and 0.1 M). The 35S-Methionine radioactivity in the eluted 
fractions was measured by liquid scintillation counting.         
 
Methylation of HIC column Fractions 
Fractions collected at each ammonium sulfate concentration were pooled and 
precipitated with 2 volumes of ice cold ethanol at -200C overnight followed by 
centrifugation at 4200 X g for 20 min. Salts were removed by passing through 
Sephadex  G-25. The rRNA content was quantitated by measuring A260. Methylation 
assays were carried out as described above in ermE methyltransferase assay using 20 
pmols of rRNA from each fraction as the substrate.                                                   
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CHAPTER 3 
RESULTS 
 
        Effect of Erythromycin on Growth Rate, Cell Viability, and Protein Synthesis of  
                                               Staphylococcus aureus            
          Erythromycin is a macrolide antibiotic that has been widely used as an 
antimicrobial agent against a variety of bacteria, especially Gram-positive cocci (Omura 
1984). Numerous studies from our lab have revealed that this antibiotic inhibits 50S 
subunit assembly as effectively as it does the protein synthesis (Champney 2003). 
Previous studies indicated that 0.5 µg/ml erythromycin impaired vital cell activities like 
the growth rate, cell viability and protein synthesis significantly in S. aureus  RN 1786 
(Champney and Tober 1998). The current set of experiments is designed to test if 
increasing concentrations of erythromycin will increasingly inhibit growth rate, cell 
viability, and protein synthesis.   
        For these experiments, S. aureus strain RN 1786 was grown in TSB with different 
concentrations of erythromycin ranging from 0.1 to 2.0 µg/ml. Growth curves are shown 
in Figure11. The results indicate that growth was inhibited in the presence of the 
antibiotic. Also, at higher concentrations of erythromycin, growth rate inhibition was 
more pronounced as evident from the increased cell doubling time.  Figure 12 A shows 
the decline in growth rate as the percent of the control growth rate as the concentration 
of erythromycin increases.     
           Cells grown in erythromycin were diluted and plated on TSB agar plates and 
colonies were counted to see the effect of erythromycin on TVC. Results in Figure 12 B   
  show that as the concentration of erythromycin increases there is a decrease in TVC.  
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Figure11 Inhibition of cell growth by erythromycin in RN 1786: Cells were grown with 
erythromycin at 0 µg/ml (■), 0.1 µg/ml (♦), 0.25 µg/ml ( ), 0.5 µg/ml (■), 1.0 µg/ml (   ), 
and 2.0 µg/ml ( ). Results are means of three experiments. Bars indicate SEM. 
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Figure 12 Percent Inhibition of Growth rate and Total Viable Counts in RN 1786 with 
Erythromycin: Cells were grown with a range of concentrations of erythromycin as 
described in Fig. 11 and the results were plotted either as (A) percent control growth 
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rate or (B) percent control TVC. Arrows indicate respective IC50 values. Results plotted 
are the means of three experiments. Bars indicate SEM. 
     
             The inhibition of protein synthesis by erythromycin was studied in RN 1786. 
Figure 13 A depicts the increased inhibition of protein synthesis in RN 1786, which 
declined with the concentration of erythromycin. Figure 13 B illustrates the decline in 
protein synthesis as percent of control protein synthesis with the arrow indicating the 
IC50 value.   
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Figure 13 Inhibition of protein synthesis in RN 1786 by erythromycin. (A) Inhibition of 
35S-methionine incorporation in RN 1786 cells treated with erythromycin at 0 µg/ml (■), 
0.1 µg/ml (♦), 0.25 µg/ml ( ), 0.5 µg/ml (▲), 1.0 µg/ml (  ), and 2.0 µg/ml ( ). (B) 
Results from A were plotted as percent control protein synthesis. Arrow indicates IC50. 
Results are the means of three experiments. Bars indicate SEM.  
           
A. 
B. 
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              IC50 was measured based on the concentration of erythromycin required for 
50% inhibition of growth rate, total viable cell counts, and protein synthesis. Results are 
given in Table1.                 
Table 1IC50Values (µg/ml) for Erythromycin Inhibition 
                              
  
   Growth  
     rate 
 
  Viable Cell     
     Count 
 
    Protein 
  Synthesis 
         
 
    0.31 ± 0.08 
 
    0.28 ± 0.06  
 
    0.21 ± 0.03 
                                
 
Arrows in Figures 12A and 12B and 13B indicate respective IC50 values. Results are the 
means of two experiments. ± indicates SEM. 
 
 
                 
Characterization of the 50S Subunit Precursor Particle 
           Multiple studies from our lab have shown that a 50S precursor particle 
accumulates in erythromycin treated cells and that it sediments along with the 30S 
subunits on the sucrose gradients of the lysates from the drug treated cells. Previously, 
studies with E. coli from our lab indicated that this 50S precursor particle contains 23S 
rRNA and 18 of  the large subunit ribosomal proteins (Usary and Champney 2001). 
Motivated by these observations, current experiments are designed to examine whether 
the same pattern could be observed in S. aureus. It is hypothesized that the 50S 
precursor particle that accumulates in erythromycin treated cells contains 23S rRNA 
whose concentration in this precursor region will increase as the concentration of 
erythromycin increases. To verify this hypothesis slot-blot hybridizations were 
performed. An additional hypothesis to be tested is that the precursor region will contain 
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a subset of S. aureus 50S ribosomal proteins. To test this hypothesis, two-dimensional 
electrophoresis was used to analyze S. aureus ribosomal proteins and the precursor 
protein content was studied by MALDI-TOF mass spectrometry. For all the studies the 
50S precursor particle used was a mixture of 50S precursor + 30S subunits. In order to 
separate the 50S precursor from this mixture, hydrophobic interaction chromatography 
was employed. 
 
Slot -Blot Hybridization for 23S rRNA Analysis 
       To quantify the amount of 23S rRNA and hence that of 50S precursor particle in the 
30S region of the drug treated cells, slot blot hybridization procedure was used. Initially 
a range of concentrations of 23S rRNA from 0.5 – 5 µg were slot blotted on the nylon 
membrane and their hybridization signal intensities were quantified by densitometric 
analysis. A biotinylated 101 base length DNA oligonucloetide was used as a probe that 
spans S. aureus 23S sequences from nucleotides 2002-2103. From this a standard 
curve was obtained for 23S rRNA which was shown in Figure 14. This standard curve 
was used to quantify 50S precursor particle amounts in erythromycin treated cells. 
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Figure 14 23S rRNA standard curve by slot blot hybridization:  23S rRNA was isolated 
from RN 1786 cells and slot blotted onto Nytran membrane at concentrations 0 µg, 0.5 
µg, 1.0 µg, 1.5 µg, 2.0 µg, and 5.0 µg. Hybridization was performed with a biotin labeled 
23S rRNA specific probe and the images were scanned by AlfaEase™ software to 
obtain IDV values. Results shown are the means of two experiments.  
 
Quantitation of the 50S Subunit Precursor Particle 
         Slot Blot hybridization with the 101 bp biotinylated DNA probe for the 23S rRNA 
was performed to characterize and quantify the 50S precursor particle in the 30S+50S 
precursor particle mixture of RN 1786 cells. Figure 15A shows the slot-blot hybridization 
results for positive (23S rRNA) and negative (16S rRNA) controls along with those for 
the 50S precursor particle. 23S rRNA showed a strong hybridization signal whereas 
there was no hybridization signal with the 16S rRNA indicating the high specificity of the 
probe for the 23S rRNA. Figure 15B shows the results obtained for 50S precursor 
particle from cells treated with different concentrations of erythromycin. Ribosomal RNA 
obtained from the 30S+50S precursor region showed increasing hybridization signal 
with increasing erythromycin concentration indicating an increasing accumulation of the 
50S precursor particle.  23S rRNA showed a strong hybridization signal.  
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Figure 15 Characterization and Quantitation of 50S precursor particle by slot blot 
hybridization: A. Ribosomal RNA was isolated from 30S subunits from control cells (16S 
rRNA), 30S subunit+50S precursor region of the erythromycin treated cells (50S 
precursor), and from the 50S subunits of the control cells (23S rRNA). 2.0 µg of each 
sample was spotted and hybridized as described in B. 
B. Ribosomal RNA from the 30S region with the 50S precursor particles of RN 1786 
cells treated with 0.5 µg/ml,1.0 µg/ml, and 2.0 µg/ml of erythromycin was isolated. 2.0 
µg of rRNA from each sample was blotted onto Nytran membrane along with 2.0 µg of 
23S rRNA as positive control and hybridized with a biotinylated 23S rRNA specific 
probe. Images were scanned on AlfaEase™ and the amount of 23S rRNA in each 
sample was quantified from the 23S rRNA standard curve as described in Methods.  
         
             
2.0 23S rRNA 0.5 1.0 
50S precursor particle at 
different erythromycin 
concentrations (µg/ml) 
A. 
 16S 
rRNA 
  50S 
Precursor 
23S 
rRNA 
B. 
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            From the IDV values (Table 2) obtained for images in Figure 15B, the 
percentage of 23S rRNA and hence the 50S precursor present in each sample of 30S + 
50S precursor mixture was calculated as described in Methods. These results were 
tabulated in Table 3. 
Table 2 IDV values for the images in Figure 15B 
                                 
 
 
 
 
 
 
 
Images were scanned by AlfaEase™software and from the IDV values obtained, 
percentage of 50S precursor in each sample was calculated using the 23S rRNA 
standard curve (Figure 14). Results are the means of three experiments. + indicates 
SEM.  
 
Table 3 Quantitation of 50S precursor particle 
                               
     
Concentration of 
Erythromycin 
    (µg/ml) 
 
    % Protein    
    synthesis 
  
% 50S precursor/ 
     Total RNA  
 
       0.5 
 
 
      1.0 
 
 
      2.0 
 
    15.8 + 1.01 
  
     
     8.8 + 1.55 
 
  
     6.6 + 1.41 
 
     15 + 2.42 
 
 
     22 + 3.16 
 
 
     57 + 4.71  
 
Ribosomal RNA was isolated from RN 1786 cells treated with increasing concentrations 
of erythromycin. The amount of 23S rRNA in the 30S+50S precursor region was 
quantified by slotblot hybridization followed by scanning with AlfaEase™software. 
Results shown are the means of three experiments. + indicates SEM.     
Concentration of   
  Erythromycin 
        (µg/ml) 
  
      Normalized  
       Mean IDV 
 
          0.5 
 
        1.0 
 
        2.0 
 
    83640 + 198 
 
   111366 + 229  
 
   157420 + 272 
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           These results indicate that there was an increased accumulation of 50S 
precursor particle as the concentration of erythromycin was increased. At 2.0 µg/ml 
erythromycin, 57% of the rRNA from the 30S+50S precursor mixture was 23S rRNA 
indicating there could be 43% 16S rRNA. The decreases in protein synthesis rates and 
the viable cell counts along with the simultaneous increases in the 50S precursor 
particle accumulation as a function of erythromycin concentration are shown in Figure 
16.                                                             
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Figure 16 Comparison of effect of erythromycin on different cellular activities in RN 
1786: protein synthesis (O), viable cell count (O), and percentage of 50S precursor 
particle (. ). Results shown are the means of three experiments. Bars indicate SEM. 
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Two- dimensional Gel Electrophoresis of S. aureus Ribosomal Proteins 
 
       Two dimensional gel electrophoresis was performed to analyze the ribosomal 
proteins of S. aureus that has not been studied previously. Both 30S and 50S ribosomal 
subunit proteins of S. aureus were analyzed to establish their electrophoretic mobility 
patterns. SDS gel electrophoresis with molecular weight standards was carried out in 
the second dimension for molecular weight estimates of ribosomal proteins. Figures 17 
and 18 show the gel patterns for 50S and 30S subunits from control RN 1786 cells 
respectively. Thirty five protein spots were identified in the 50S gel and twenty-one 
spots in the 30S gel are seen. 
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Figure 17 SDS-2D gel electrophoresis of 50S ribosomal subunits of S. aureus RN 1786. 
Molecular weight standards are marked on the left.     
          
                    
                                                                   
Figure 18 SDS 2D gel electrophoresis of 30S subunits of S. aureus RN 1786. Molecular 
weight standards are indicated on the left. 
         
           Molecular weight standards were electrophoresed simultaneously. Individual 
proteins were identified by correlating their corresponding molecular weights on the gel 
to those predicted from the genome analysis (Holden et al. 2004).  Characteristics of 
Staphylococcus aureus ribosomal proteins as predicted by genome analysis are given 
in Tables 4 (50S) and 5 (30S).  
 66 
45 
32 
21 
14 
45 
32 
21 
14 
66 
 66 
Table 4  Characteristics of S. aureus 50S ribosomal proteins predicted by the genome 
analysis (Holden et al 2004) 
  50S 
Protein    Gene ID 
Sequence 
Location 
Predicted No. 
of Amino acids 
Predicted 
Post. 
Translational 
Modifications 
Predicted 
Mol wt 
(KDa) 
L1 2860898 rpIA/SAR0543 229  24.4 
L2 2860899 rpIB/SAR2332 277  30 
L3 2860900 rpIC/SAR2335 220 Met Gln 150 23.5 
L4 2860901 rpID/SAR2334 207  22.3 
L5 2860902 rpIE/SAR2323 179  20.1 
L6 2860903 rpIF/SRA2320 178  19.6 
L7/L12 9860907 rpIL/SAR0545  
 Ac Ser 1,  
 Met Lys 81 12.6 
L8   122   
L9 2860904 rpsF/SAR0362 148  16.3 
L10 2860905 rpIJ/SAR0544 166  17.5 
L11    
Tri Met Ala 1, 
Tri Met Lys 3, 
Tri Met Lys 39 14.7 
L12 2860906 rpIK/SAR0542 140   
L13 2860908 rpIM/SAR2301 145  16.2 
L14 2860909 rpIN/SAR2325 122  13 
L15 2860910 rpIO/SRA2316 146  15.4 
L16 2860911 rpIP/SAR2328 144 
 Met Met 1,  
 Arg der 81 16.1 
L17 2860912 rpIQ/SAR2308 122  13.6 
L18 2860913 rpIR/SRA2319 119  12.9 
L19 2860914 rpIS/ SAR1217 116  13.2 
L20 2860915 rpIT/SAR1758 118  13.5 
L21 2860916 rpIU/SAR1727 102  11.2 
L22 2860917 rpIV/SAR2330 117  12.7 
L23 2860918 rpIW/SAR2333 91  10.4 
L24 2860919 rpIX/SAR2324 105  11.4 
L25 2860920 rpIY/SAR0502 217  23.7 
L26      
L27 2860921 rpmA/SAR1725 94  10.1 
L28 2860922 rpmB/SAR1200 62  6.8 
L29 2860923 rpmC/SAR2327 69  7.9 
L30 2860924 rpmD/SRA2317 59  6.4 
L31 2860925 rpmE/SRA2208 84  9.5 
L32 2860161 rpmF/SAR1101 57  6.3 
L33 type1  2860162 rpmG1/SAR1628 49  Met Ala 1 5.7 
L33 type 2 2860163 rpmG2/SAR1345 49  5.8 
L33 type 3 2860164 rpmG3/SAR0538 47  5.7 
L34 2860165 rpmH/SAR2800 45  5.3 
L35 2860166 rpmI/SAR1759 66  7.5 
L36 2860167 rpmJ/SAR2312 37  4.1 
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Table 5 Characteristics of S. aureus 30S ribosomal proteins predicted by genome 
analysis (Holden et al. 2004) 
 
  Protein  Gene ID 
Sequence 
Location 
Predicted No. 
of Amino acids 
Predicted Post. 
Translational 
Modifications 
Predicted 
Mol wt 
(KDa) 
S1 2860032 SAR1485 391  43.1 
S2 2860173 rpsB/SAR1232 255  28.9 
S3 2860174 rpsC/SAR2329 217  23.9 
S4 2860175 rpsD/SAR1797 200  22.8 
S5 2860176 rpsE/SRA2318 166 1 Ac Ala 17.6 
S6 2860177 rpsF/SAR0362 98  11.4 
S7 2860178 rpsG/SAR0551 156  17.6 
S8 2860179 rpsH/SRA2321 132  14.7 
S9 2860180 rpsI/SRA2300   14.4 
S10 2861446 rpsJ/SAR2336 102  11.4 
S11 2661447 rpsK/SAR2310 129 1 Met Ala 13.7 
S12 2861448 rpsL/sar0550 137 
88 Asp 
derivative 15.1 
S13 2861449 rpsM/SAR2311 121  13.5 
S14 2861450 rpsN/SRA2322 61  7.1 
S15 2861451 rpsO/SAR1249 89  10.4 
S16 2861452 rpsP/SAR1214 91  10.1 
S17 2861453 rpsQ/SAR2326 87  10 
S18 2861454 rpsR/SAR0362 80 1 Ac Ala 9.4 
S19 2861455 rpsS/SAR2331 92  10.4 
S20 2861456 rpsT/SAR1663 83  8.8 
S21 2861457 rpsU/SAR1652 58  6.8 
 
                                                    
MALDI-TOF Mass Spectrometry 
          The 50S precursor protein analysis was done by MALDI-TOF mass spectrometry. 
The sensitivity of this method makes it possible to identify the 30S and 50S ribosomal 
proteins based on their molecular weights. Ribosomal protein samples were prepared 
by acetic acid extraction and acetone precipitation as described in Methods and 
samples were sent for the mass spectrometry analysis to the Columbia University Core 
Facility, NY.  Figures 19, 20, and 21 show the mass spectra of 30S subunits, 50S 
subunits, and the 50S precursor region proteins. Proteins were identified based on their 
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molecular weights predicted from the genome analysis (Holden et al. 2004). Because 
the post translational modifications of S. aureus proteins are not known,  
E. coli modifications were taken into consideration for the accurate determination of 
masses (Tables 4 and 5).  In the 30S spectra, 17 proteins were identified. High 
background noise prevented identification of high molecular weight proteins S2 and S4 
in the spectra. A total of twenty-five 50S proteins were identified as well. Importantly, in 
the 50S precursor region, 17 of 30S proteins and 16 of 50S proteins were identified. A 
comparison of the E. coli and S. aureus 50S precursor compositions is given in Table 9 
in Discussion.  
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Figure 19 MALDI-TOF mass spectra for S. aureus 30S ribosomal proteins. Ribosomal 
proteins were dissolved in TFA, mixed with matrix, and spotted onto stainless steel 
target. Each individual spectrum represents a specific molecular weight range as 
indicated. A. 4000 to 8000 Da, B. 7500 to 12000 Da, C.12000 to 20000 Da, D.19000 – 
30000 Da. 
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Figure 20 MALDI-TOF mass spectra for S. aureus 50S ribosomal proteins. Ribosomal 
proteins were dissolved in TFA, mixed with matrix, and spotted onto stainless steel 
target. Each individual spectrum represents a specific molecular weight range as 
indicated. A. 4000 to 8000 Da, B. 7500 to 12000 Da, C. 12000 to 20000 Da, D. 19000 to 
30000 Da. 
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Figure 21 MALDI-TOF mass spectra for S. aureus ribosomal proteins from 50S 
precursor region of erythromycin treated cells. Ribosomal proteins were dissolved in 
TFA, mixed with matrix, and spotted onto stainless steel target. Each individual 
spectrum represents a specific molecular weight range as indicated. 30S proteins are 
indicated in black and 50S proteins in red. Each individual spectrum represents a 
specific molecular weight range as indicated. A. 4000 to 8000 Da, B. 7500 to 12000 Da, 
C. 12000 to 20000 Da D. 19000 to 30000 Da. 
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Separation of the 50S precursor particle by 
hydrophobic interaction chromatography 
 
           Hydrophobic interaction chromatography has been used to separate ribosomal 
subunits previously (Kirillov 1978, Saruyama 1986). In the current studies, ribosomal 
subunits were adsorbed on to Octyl Sepharose 6B matrix and were eluted from the 
column with a reverse step wise concentration gradient of ammonium sulfate. Due to 
their inherent differences in the hydrophobicity, subunits were eluted at different 
concentrations of ammonium sulfate.     
         Subunits labeled with 35S-Methionine were loaded onto the column, fractions were 
collected, 35S-methionine was counted by liquid scintillation counting, and the elution 
pattern was plotted. Figure 22 indicates the elution profiles of 30S subunits and 50S 
subunits from control cells and the 30S and 50S precursor mixture from erythromycin 
treated cells. Figure 22 A shows that 30S subunits from the control cells were eluted at 
1.25 M ammonium sulfate. Figure 22 B shows that the 50S subunits were eluted at  
0.25 M ammonium sulfate. Importantly, Figure 22 C indicates that a major portion of the 
30S and 50S mixture from the erythromycin treated cells was eluted at 0.25 M, a 
concentration at which the 50S subunits were eluted. This observation reinforces our 
previous finding that the 30S region of the erythromycin treated cells contains 50S 
precursor particle (Usary and Champney 2001) and that it could be separated by HIC.  
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Figure 22 Ribosomal Subunit Purification by Hydrophobic Interaction Chromatography: Use 
of Octyl Sepharose 6B hydrophobic interaction chromatography column and step wise 
ammonium sulfate gradient for the purification of 35S Methionine labeled (A) 30S subunits, 
(B) 50S subunits, and (C) 50S precursor particle. Results are the means of two 
experiments.  
 
Methylation of column fractions  
            Fractions eluted at different ammonium sulfate concentrations from the HIC 
column were tested for ermE methyltransferase mediated ribosomal RNA methylation to 
establish their substrate role. The methylation assay was carried out as described for 
the ermE methyltransferase activity in the Methods section. Figure 23 demonstrates the 
results obtained for the erm methylation using 3H S- adenosyl methionine as the methyl 
B. C. 
A. 
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group donor.  Fractions obtained from 1.5 M- 0.75 M ammonium sulfate showed 
minimal methylation activity, whereas fractions eluted at 0.5 M and 0.25 M ammonium 
sulfate showed significant methylation activities of which the 0.25 M fractions showed 
the maximum methylation activity. These results further substantiate our earlier findings 
that a 50S precursor particle could be eluted at 0.25 M ammonium sulfate and it could 
act as a substrate for ermE methyltransferase, and fractions obtained from pure 30S or 
50S subunits were not methylated by this enzyme. 
        Previous findings from our laboratory (Champney et al. 2003) have shown that 50S 
precursor particle accumulates in the 30S region of the sucrose gradients of the 
erythromycin treated cells. Our current findings are in agreement with the previous data 
and suggest a method to purify the 50S precursor from the 30S+50S precursor mixture.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 75 
 A.                                                                 B. 
0
5000
10000
15000
20000
25000
3 H
 
M
et
hy
la
tio
n
 
M
ea
n
 
C
PM
23
S 
rR
N
A
16
S 
rR
N
A
 
50
S 
Pr
ec
u
rs
o
r 
1.
5 
M
1.
25
 
M
1.
0 
M
0.
75
 
M
0.
5 
M
0.
25
 
M
Substrate
          
0
2000
4000
6000
8000
3 H
 
M
et
hy
la
tio
n
 
 
M
ea
n
 
C
PM
1.
5 
M
1.
25
 
M
1.
0 
M
0.
75
 
M
0.
5 
M
0.
25
 
M
Concentration of Ammonium Sulfate (M)
 
 Figure 23 ermE methylation of HIC column fractions: Methylation was carried out as 
described for ermE methyltransferase activity with fractions obtained at different 
ammonium sulfate concentrations used as substrates. 3H methyl RNA was counted by 
liquid scintillation counting and results were shown as bar graphs. A. Methylation shown 
along with positive (23S rRNA) and negative (16S rRNA) controls. B. Enlarged version 
of (A) indicated in blue box. Results are the means of two experiments.  
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Binding of 14C Erythromycin to 50S subunits and 50S precursor particle 
          Studies in E. coli from our lab indicated that erythromycin binds to the 50S 
subunits and the 50S precursor particle in a 1:1 ratio (Usary & Champney 2001). In view 
of this finding, it was hypothesized that erythromycin will bind to both the 50S subunits 
and the 50S precursor particle of S. aureus because of the similar secondary structure 
of its 23S rRNA to that of E. coli (Garrett et al. 2000, Thompson and Dahlberg 2001).  
For this set of experiments the binding of 14C erythromycin to the 50S precursor particle 
was examined with 50S subunits as positive controls (Figure 24).         
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Figure 24 Binding of 14C Erythromycin to the 50S subunits (♦) or to the 50S precursor 
particle (■). Five fold excess of 14C erythromycin was added to a range of 
concentrations (0-80 pmols) of either 50S subunits or the 50S precursor particle. The 
binding assay was carried out as described in Methods. Bars indicate SEM. Results are 
the means of three experiments normalized with control 30S subunits.  
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          KM values for this binding are tabulated in Table 6. These results indicate that 
erythromycin does bind to the 50S precursor particle but with a lesser affinity than that 
of the 50S subunits.  
KM for 14C Erythromycin binding to different substrates 
    
 
                        
 
                             
 
Table 6 KM for 14C Erythromycin binding to different substrates 
 
Characterization of ermE Methyltransferase Enzyme 
        The ermE methyltransferase confers erythromycin resistance by dimethylating N-6 
of A2085 in S. aureus 23S rRNA (Skinner 1982).  It also methylates protein free 23S 
rRNA from Bacillus subtilis and E. coli (Skinner 1983, Vester & Douthwaite 1994). All 
structural elements needed for ermE recognition are present in domain V of 23S rRNA. 
In the current studies this enzyme was purified and examined for its substrate specificity 
in S. aureus. This work tests the hypothesis that the ribosomal 50S precursor particle 
that accumulates in erythromycin treated cells is the in vivo substrate for ermE 
methyltransferase. 
        For these studies, an ermE methyltransferase gene with a C-terminal His-tag was 
used that was cloned into perm60 vector for inducible expression in E. coli DH1. Ni-
affinity chromatography was used purify this His- tagged enzyme as described in 
            
          Substrate 
 
           KM  
 
     50S subunits 
   50S Precursor Particle 
 
        109 nM 
        154 nM 
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Methods. The integrity of ermE methyltransferase enzyme in the eluate fractions was 
assessed by Western blotting and the substrate specificity was studied by 
methyltransferase assay. 
 
Western Blotting of ermE Enzyme 
              
 For
 
the ermE methyltransferase with C-terminal His-tag, Western blotting was 
done using Anti-6His mouse monoclonal antibody (Figure 25). Analysis was performed 
on the crude enzyme fraction obtained by the high salt wash of the perm60 ribosomes, 
the wash fraction of the Ni-affinity column and the eluate fraction where the enzyme is 
eluted from the column with 250 mM imidazole. 
                                                       
 
 
                  
 
 
 
 
 
 
 
 
 
 Figure 25 Western Blotting of ermE methyltransferase: ermE enzyme was purified on 
 Ni-affinity column as described in Methods and 20µg of each fraction was subjected to 
12% PAGE followed by Western blotting with anti-6His monoclonal antibody. HRP 
substrate on the membrane was detected by North 2 South Chemilumenescent kit and 
exposed to X-ray film.  Lanes 1. High salt wash of the ribosome (crude enzyme fraction) 
2. Wash fraction 3. Eluate fraction. Molecular weight standards are indicated in KDa. 
Arrow indicates ermE methyltransferase on the blot. 
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             High concentrations of the enzyme were expected to be present in the crude 
and the eluate fractions and with efficient binding onto the Ni-affinity column it should 
not be eluted in the wash fraction. In agreement with our prediction, Western blotting 
results showed intense signal both in the crude as well as the eluate fractions. There 
was some non specific elution of the enzyme in the wash fraction but at very low levels. 
In Figure 25, enzyme was detected at the expected molecular size of 45 KDa. 
Importantly, there was no breakdown of the enzyme even with overloading on the gel.  
 
ermE methyltransferase enzyme assay 
              The premise of this set of experiments was that a 50S precursor particle that 
accumulates in the 30S region of sucrose gradients of erythromycin treated cells was 
the in vivo substrate for erm E methyl transferase. The 50S precursor particle was 
tested as a substrate for the ermE methyltransferase in an in vitro methylation assay 
along with 23S rRNA, 16S rRNA, and 50S subunits using 3H S- Adenosyl methionine as 
a methyl group donor. The activity of ermE methyltransferase was tested as a measure 
of enzyme mediated incorporation of 3H methyl groups into the respective substrate.  As 
evident from the Figure 26, 23 S rRNA was the best in vitro substrate as already studied 
(Vester and Douthwaite 1994). Apart from 23S rRNA, it was the 50S precursor particle 
that was methylated to a considerable extent by the enzyme. It is important to note that 
fully assembled 50S subunits were not methylated by the enzyme and neither were 30S 
subunits or 16S rRNA. 
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Figure 26 ermE methyltransferase activity assay: The assay was conducted as 
described in Methods with each reaction mixture containing 20 pmols of respective 
substrate, 3 µCi of 3H SAM and 30 pmols of ermE methyltransferase. The activity was a 
measure of 3H Methyl RNA formed as indicated by bar graphs. Results are the means 
of three experiments. Bars indicate SEM.  
 
 
Inhibition of ermE methylation by MLS drugs   
        It was hypothesized that MLS drugs will inhibit ermE methyltransferase activity 
owing to their overlapping binding sites near the PTC. To address this hypothesis, 
macrolide, lincosamide, and streptogramin B drugs were tested for their ability to inhibit 
ermE methyltransferase activity. Erythromycin, lincomycin and virginiamycin S were 
used in these studies as representative MLS antibiotics respectively.  ErmE 
methyltransferase activity assays were conducted as previously but in the presence of a 
range of concentrations of the antibiotics (Figure 27). 
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 Figure 27 Concentration dependent inhibition of ermE methylation of 50S precursor 
particle by MLS antibiotics: Inhibition assays were carried out as described in Methods 
and inhibition of 3H Methyl RNA formation was plotted as a function of the drug 
concentration for erythromycin, or lincomycin, or virginiamycin S. Results are the means 
of three experiments. Bars indicate SEM. 
 
                                              
       The results in Figure 27 indicate that all the three of the antibiotics inhibited 
methylation activity as a function of their concentration. Table 7 lists the inhibition 
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constants (Ki) for the MLS drugs. Results indicate that they have similar Ki values for 
ermE methyltransferase. 
                
Table 7 Inhibition Constants for MLSB antibiotics for ermE methyltransferase activity 
 
       Drug 
 
           Ki (µM) 
 
Erythromycin 
Lincomycin  
Virginiamycin S 
 
           99.2 
           132 
           108 
 
. 
Competition Experiments 
          MLS antibiotics and ermE methyltransferase bind to the domain V sequences of 
23S rRNA sharing a common binding site near the A2058 of E. coli (equivalent to A 
2085 in S. aureus) (Skinner 1983). Earlier results from this study have shown that ermE 
methyltransferase can bind to and methylate the 50S precursor particle (Figure 26). 
Results in Figures 24 and 27 have also shown that MLS antibiotics can bind to the 50S 
precursor particle to inhibit Erm mediated methylation. Together these findings suggest 
that the 50S precursor particle is a substrate where there could be a potential 
competition between ermE methyltransferase and MLS antibiotics. Current experiments 
were designed to investigate this competition. Competition assays were performed as 
described with either 3H SAM or 14C Erythromycin. Results in Figure 28 show that 
methylation activity and, hence, incorporation of 3H SAM into the 50S precursor particle 
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increased as the concentration of ermE methyltransferase increased even in the 
presence of erythromycin at 80 µM concentration, suggesting that increasing 
concentrations of the enzyme displaced erythromycin from its binding to the precursor. 
When the same assays were conducted to study binding of 14C erythromycin as the 
enzyme concentration increased, as Figure 29 indicates, erythromycin was lost from the 
precursor particle. 
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Figure 28 Competition between ermE methyltransferase and erythromycin: 3H 
methylation of the 50S precursor particle with increasing ermE methyltransferase. 
Concentration of erythromycin was kept constant at 80 µM. Bars represent SEM. 
Results are normalized with 30S control and are the means of three experiments.  
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Figure 29 Competition between ermE methyltransferase and 14C Erythromycin: 
Decreased 14C Erythromycin binding to 50S precursor particle with increasing ermE 
methyltransferase. Bars represent SEM. Results are the means of three experiments. 
 
           . Figure 30 shows the increase in 3H RNA methylation and the decrease in 14C 
erythromycin binding simultaneously with increasing ermE concentrations. Results of 
these competition experiments indicate that the binding of either of the substrates to the 
50S precursor particle finely hinges on their concentration. The Kd of ermE 
methyltransferase and the Ki erythromycin inhibition are given in Table 8.        
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Figure 30 Competition between ermE methyltransferase and erythromycin for the 50S 
precursor particle: Increased 3H methylation (●) and decreased 14C erythromycin 
binding (■) with increasing ermE methyltransferase concentration.  
 
 
Table 8 Comparison between Kd and Ki of ermE methyltransferase and erythromycin 
for the 50S precursor particle 
 
                                  
Competitor  
 
    Kd or Ki (µM) 
 
ermE methyltransferase 
Erythromycin 
 
        0.334  
        99.2 
                        
            
             This set of experiments confirms that ermE methyltransferase can actively 
displace erythromycin from 50S precursor particle to bring about methylation leading 
erythromycin resistance. A single molecule of ermE methyltransferase can repeat 
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catalysis cycles on different substrate (50S precursor) particles, whereas erythromycin 
binds to the substrate in a 1:1 stoichiometric fashion. This explains the low Kd of erm 
methyltransferase versus the high Ki of erythromycin. Results of these competition 
experiments indicate that the binding of either of the substrates to the 50S precursor 
particle finely hinges on their concentrations. 
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CHAPTER 4 
DISCUSSION 
 
                Macrolides, lincosamides, and streptogramin B compounds are clinically 
important antibiotics that bind to the large ribosomal subunit close to the PTC (Moazed 
and Noller 1987, Spahn and Prescott 1996, Kirillov 1999). MLSB resistance caused by 
23S ribosomal RNA methylation is a well studied mechanism. The Erm class of methyl- 
transferases are responsible for this resistance phenomenon (Gaynor and Mankin 
2003). Many studies have described the constitutive and inducible erythromycin 
resistance resulted from the action these enzymes. Much of the information about this 
mechanism was gained by using purified 23S rRNA as the in vitro substrate for erm 
methyltransferases (Uchiama 1985, Nielsen et al. 1999). Studies have shown that 50S 
subunits are not substrates for these enzymes (Skinner 1983, Weisblum 1995). More 
over, the absence of protein free 23S rRNA in the cells leaves a gap in identifying the 
nature of the true in vivo substrate for this class of methyltransferases. Also, not much is 
known about the interplay between the enzyme and MLSB class of antibiotics at their 
common binding site on the PTC. The current studies were undertaken to better 
understand the true nature of the substrate methylated in vivo by the ermE 
methyltransferase enzyme and to understand the competition between MLSB drugs and 
the enzyme for the same substrate. 
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Growth of S. aureus RN 1786 with erythromycin 
          Erythromycin is a well known protein synthesis inhibitor. Studies from our lab 
have shown that ribosome subunit assembly is a second important target for this 
macrolide antibiotic and that the stalled 50S ribosomal precursor particle accumulates in 
the 30S region of the sucrose gradients of lysates from the drug treated cells  
(Champney 2001 and 2006). The inhibitory effects of erythromycin were found to be 
equivalent on both the cellular process of protein synthesis and 50S subunit assembly. 
The formation of 30S subunits was not affected and the pre-existing 50S particles were 
not  broken down (Champney and Burdine 1995, Chittum and Champney 1995, 
Champney and Burdine 1996).  
           In this current work, Figure 13 indicates an 82% inhibition in protein synthesis at 
0.5 µg/ml erythromycin, which is in good agreement with the previous studies that 
showed 70% inhibition of protein synthesis at the same concentration (Champney and 
Tober 1998). Growth rate, cell viability, and protein synthesis (IC50) were inhibited by 
50% at 0.28 µg/ml, 0.31 µg/ml and 0.21 µg/ml erythromycin respectively (Table 1). 
Similar IC50s for all the three cellular activities indicate a direct correlation between the 
inhibition of protein synthesis and reduction in growth rate and cell viability.  
 
Characterization of 50S precursor particle 
          Experiments were done to characterize the 50S precursor particle that 
accumulates in the 30S region of sucrose gradients of lysates from erythromycin treated 
cells. Previous studies from our lab in E. coli showed the presence of a 50S precursor 
particle in the 30S region of sucrose gradients by pulse-chase labeling and antibiotic 
binding studies (Usary and Champney 2001). In these previous studies, the analyses 
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showed a decreased 50S associated rRNA in erythromycin treated cells. Identity of 23S 
rRNA sequences in the precursor region was confirmed by Northern hybridization using 
a 23S specific DNA probe.  Results of these experiments showed that in control cells 
75% of the 23S rRNA was present in the 50S region, whereas in drug treated cells, 40% 
was found in the 50S region and 35% in the 30S region.  These studies are the 
background work for the present studies to examine the pattern of accumulation and 
quantitation of the 50S precursor particle amounts in S. aureus cells. 
 
Characterization of rRNA by slot blot hybridization: 
          Characterization of the ribosomal RNA content of the 50S precursor particle was 
done by slot blot hybridization. The results indicated the presence of 23S ribosomal 
RNA in the 30S region of the erythromycin treated cells confirming the co-sedimentation 
of the 50S precursor particle in this region (Figure 15A). These results indicated that the 
proportion of 23S rRNA of this region increased with the concentration of erythromycin 
(Figure 15B). The percentage of 50S precursor increased from 15% to 57% as the 
concentration of erythromycin increased from 0.5 µg/ml to 2.0 µg/ml (Table 3). This 
implies that as the drug concentration increased there was an increased arrest of the 
50S ribosomal subunit assembly that in turn resulted in increased accumulation of the 
50S precursor particle leading to a higher proportion of 23S rRNA at elevated 
erythromycin concentrations in the 30S region of erythromycin treated cells.  
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Characterization of ribosomal proteins by two-dimensional electrophoresis: 
          In addition to the rRNA identification, ribosomal proteins of S. aureus were 
examined. The electrophoretic separation pattern of small and large subunit ribosomal 
proteins of S. aureus has not been studied before. Current studies used two- 
dimensional gel electrophoresis to analyze the ribosomal proteins of this organism 
(Figures 17 and18).  An acidic first dimension separation at pH 5.0 and second 
dimensional electrophoresis in the presence of SDS were carried out to enable 
molecular weight determinations. In the current studies 35 50S proteins and all 21 of the 
30S proteins were found in the gels. Their molecular weighs correlated with the 
molecular weights of S. aureus ribosomal proteins predicted from its genome analysis 
(Holden et al. 2004).  Additional high molecular weight proteins that were observed in 
the 50S gel pattern were believed to be ribosomal binding proteins that co-sediment 
with the large ribosomal proteins on the sucrose gradients. These experiments are the 
first to study the ribosomal subunit proteins of S. aureus. Dekio and Jidoi analyzed 70S 
ribosomal proteins of Staphylococcus aureus Smith and Staphylococcus epidermidis 
IAM 12012 as a part of their phylogenetic studies (Dekio and Jidoi 1983). They detected 
25 basic and 11 acidic proteins in the 70S subunits of S. aureus. In the current studies, 
the whole complement of 50S as well as 30S proteins was detected by two-dimensional 
electrophoresis. 
 
Identification of 50S precursor proteins by MALDI-TOF mass spectrometry: 
           Attempts were also made to identify S. aureus ribosomal proteins by mass 
spectrometry.  The protein composition of the 50S precursor particle was determined by 
the MALDI TOF mass spectrometry method (Figures 19-21). Mass spectrometry is a 
 91 
powerful tool for the identification and characterization of proteins and peptides. 
Progress in the time of flight (TOF) instrumentation has improved the quality of MALDI 
mass spectra to the point where the masses of molecules smaller than 30,000 Da can 
typically be measured to an accuracy of 1 Da or better (Colby and Reilly 1994, Brown 
and Lennon 1995, Whittal et al. 1995). Accurate determination of the masses made it 
possible to identify seventeen 30S proteins and twenty-five 50S proteins by correlating 
with the masses predicted from the genome sequence. High noise in the 20-30 KDa 
region hindered the identification of high molecular weight proteins like L2 and L3. Also, 
in general, large proteins are often difficult to observe by MALDI-TOF in the presence of 
smaller proteins because of competitive ionization. Small proteins ionize readily 
compared to large proteins (Kaufmann 1995). Because the post translational 
modifications of S. aureus ribosomal proteins are not known, ionized species of the 
proteins could not be reliably identified in these spectra. 
             Importantly, the protein composition of the 50S precursor region of the 
erythromycin treated cells was analyzed by MALDI-TOF mass spectrometry. Seventeen 
peaks corresponding to 30S proteins were detected in this region. Significantly, sixteen 
50S proteins were also detected in this region. Previously, two natural 50S precursors 
were studied in E. coli, a 32S particle, (p150S), and a 43S particle (p250S) (Homann and 
Nierhaus 1971, Nierhaus and Homann 1973). They both contain 23S and 5S rRNA with 
different proteins compositions. Previous studies in E. coli from our lab identified 18 
large subunit ribosomal proteins in the 50S precursor particle region that accumulated in 
erythromycin treated cells (Usary and Champney 2001). Current studies identified 11 
proteins of those 18 proteins identified in E. coli. They are L5, L9, L10, L11, L13, L15, 
L16, L17, L18, L22, and L23 (Table 9). Notably, L15 and L16 that were implicated in 
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erythromycin interactions of the large subunit in E. coli (Nierhaus 1982) were identified 
in the current studies also. L1-L4 identified earlier in E. coli could not be detected in the 
current studies. As mentioned earlier, difficulties in the detection of higher molecular 
weight proteins might have evaded their identification. Moreover, the assembly map of 
S. aureus is not available to make accurate comparisons. Information about individual 
proteins of S. aureus is needed to better understand the significance of the presence of 
specific proteins in the precursor region.  Table 9 illustrates the composition of 50S 
precursor particles as described by different studies.  
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Table 9 Comparison of 50S precursor protein composition from different studies. 
 
 
 50S ribosomal 
        Protein 
 
 
    E. colia 
    (+ ery) 
 
  S. aureusb 
   (+ ery) 
       L1 
       L2 
       L3 
       L4 
       L5 
       L6 
       L7/L12 
       L8 
       L9/L10 
       L11 
       L12 
       L13 
       L14 
       L15 
       L16 
       L17 
       L18 
       L19 
       L20 
       L21 
       L22 
       L23 
       L24 
       L25 
       L26 
       L27 
       L28 
       L29 
       L30 
       L31 
       L32 
       L33 
       L34 
       L35 
       L36 
          + 
          + 
          + 
          + 
          + 
          + 
          + 
          −       
          + 
          + 
          − 
          + 
          − 
          + 
          + 
          + 
          + 
          − 
          − 
          − 
          + 
          +   
          − 
          + 
          + 
          − 
          − 
          − 
          − 
          − 
          − 
          − 
          − 
          − 
          −      
       ND 
       ND 
       ND 
       ND 
         + 
       ND 
         − 
         − 
         + 
         + 
         − 
         + 
         + 
         + 
         + 
         + 
         + 
         + 
         + 
         − 
         + 
         + 
         − 
         − 
         − 
         − 
         − 
         + 
         + 
         − 
         + 
         − 
         − 
         − 
         − 
 
 (+) Present, (−) Absent, (ND) Not Detected in the current studies. 
 a: Usary  and Champney 2001, b: Current studies 
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Separartion of 50S precursor particle by HIC 
        All prior studies of the 50S precursor particle had been performed as a mixture with 
the 30S subunits of erythromycin treated cells.  Previous studies had not attempted to 
purify the 50S precursor particle from the 30S region. HIC was previously used to isolate 
ribosomal subunits in E. coli, Thermus thermophilus, and Halobacterium as an alternative 
to zonal centrifugation (Kirillov et al. 1978, Ramakrishnan et al.1986). In these previous 
studies HIC was shown to be able to separate 33S and 47S particles, which are partially 
unfolded forms of 50S. E. coli 30S subunits isolated by this method were active in protein 
synthesis in vitro and co-migrated on sucrose gradients with subunits isolated by zonal 
sucrose gradient centrifugation. HIC separates subunits based on their difference in 
hydrophobic interaction with hydrophobic matrix material at very low concentrations of 
magnesium.  Consequently, HIC was exploited as a method for purification of the 50S 
precursor particle from its mixture with the 30S subunits of erythromycin treated cells.  
         Results from Figure 22 showed that from the Octyl Sepharose column, 30S 
subunits were eluted first at a higher ammonium sulfate concentration of 1.25 M 
whereas 50S subunits were retained longer and eluted at a lower salt concentration of 
0.25 M. An important observation was that when a 30S+50S precursor mixture was 
applied on to the column, a significant proportion of the sample eluted at 0.25 M 
ammonium sulfate, a concentration at which 50S subunits were eluted.   
        The eluted samples from the 30S+50S precursor mixture were further tested for their 
ability to be methylated by the ermE methyltransferase because the 50S precursor 
particle was shown to be a substrate for this enzyme but not the 30S subunits (Figure 26). 
Results of these assays revealed that the sample eluted at 0.25 M ammonium sulfate 
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acted as substrate for ermE methyltransferase, whereas the one eluting at 1.25 M did not 
(Figure 23). Samples eluted at other concentrations of ammonium sulfate also failed to 
act as substrate for ermE methyltransferase.  These results confirm the presence of 50S 
precursor in the samples eluting at 0.25M.  
          Here the separation of 50S precursor particle by HIC was attained due to the 
different conformational alterations of the 30S and 50S subunits in a medium of low 
magnesium and high salt concentration. In this state the hydrophobic interaction of the 
50S precursor particle with the hydrophobic matrix is changed.  This results in its elution 
from the octyl sepharose column at a much lower salt concentration than the 30S 
subunits making the isolation of 50S precursor particle from the former feasible. These 
studies demonstrate HIC as a potential method of purification for the 50S precursor 
particle.  
 
14C Erythromycin Binding Studies 
         The binding of erythromycin to 50S precursor particle was studied and compared 
to that to the 50S subunits (Figure 24). These studies indicated that the binding affinity 
of erythromycin to both the 50S precursor particle and 50S subunits was similar. 
Binding constants for the 50S precursor particle and 50S subunits were 109 nM and 
154 nM respectively and were 70 times that of the 30S subunits (KM= 74.63 X 102 nM). 
Previous studies from our lab in E. coli suggested that erythromycin binds to the 50S 
subunits in a 1:1 ratio. The same studies also indicated binding to the 50S precursor 
particle to be similar to that to the 50S subunits. Current studies concur with these 
previous findings.  
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             Erythromycin binding studies have shown that this drug binds to the 50S 
precursor particle with the same affinity as it does to the 50S ribosomal subunits.  The 
general location of the macrolide binding site on the large ribosomal subunit has been 
mapped by biochemical and genetic methods previously (Ettayebi and Morgan 1985, 
Mozad and Noller 1987, Vester and Garrett 1987, Weisblum 1995, Hansen and 
Douthwaite 1999, Xiong and Mankin 1999). More details have emerged from the 
crystallographic studies of archaeal and bacterial large ribosomal subunits and their 
complexes with antibiotics (Hansen and Steitz 2000, Harms  et al. 2001, Schlunzen et 
al. 2001).The X-ray structures indicated that ribosomal RNA constitutes the primary 
component of the macrolide binding site . Biochemical data revealed that macrolides 
including erythromycin interact mainly with the loop of helix 35 in domain V of 23S rRNA 
(Hansen et al. 1999, Xiong et al. 1999). Mutations or changes in posttranscriptional 
modifications in this rRNA region confer weak resistance to macrolides (Liu et al. 2000). 
          A number of nucleotide residues in the domain V of 23S rRNA interact with the 
macrolide molecule. Important contacts that contribute markedly to the strength of 
interaction of the macrolide with the ribosome are formed between the desosamine sugar 
moiety of erythromycin and the rRNA. The desosamine sugar of erythromycin and other 
related fourteen-membered macrolides form hydrogen bonds with nucleotide residues 
A2058 and 2059 (E. coli numbering). The nucleotide at position 2057 may also be 
involved in hydrogen bonding with the C5 of the desosamine sugar (Schlunzen et al. 
2001) of erythromycin. In the case of 15 or 16 membered ring macrolides, the same 
nucleotide may establish hydrophobic bonding with the lactone ring (Hansen et al. 2002). 
In addition, the desosamine sugar can potentially interact with the backbone phosphate 
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oxygen of G2505. Interaction of the lactone ring accounts for more than 25% of the free 
energy of binding of macrolides (Garga-Ramos et al. 2002).  
             Ketolides are the most recently introduced generation of modified macrolides. 
They contain a 11, 12- carbamate ring where macrolides have free hydroxyl groups. 
The 11-OH and 12-OH lactone hydroxyls of erythromycin and related drugs form a 
hydrogen bond with O4 of U2609 whereas the carbamate ring of ketolides forms 
hydrogen bonds with this group. But this interaction is more important for ketolides than 
for erythromycin group of macrolides because a mutation of U2609 confers resistance 
to ketolides but not to macrolides (Garga-Ramos et al. 2002). 
 
ermE methyltransferase Studies 
       In the present work, the true in vivo substrate for the ermE methyltransferase 
enzyme was probed. Previous studies showed the 50S precursor particle as an 
important substrate for ermC methyltransferase enzyme in S. aureus (Champney et al. 
2003). These studies have also shown that fully assembled 50S subunits were not 
methylated as others have found (Skinner et al. 1983, Weisblum 1995).This finding was 
consistent with a model that predicted the accumulation of a stalled 50S precursor 
particle in erythromycin treated cells. Relief from inhibition and continued particle 
synthesis can occur only by precursor methylation that reduces erythromycin binding to 
50S subunits.   
          The same studies proposed a model to account for this activity. In wild-type 
organisms, erythromycin stalls the 50S particle formation, and cellular ribonucleases 
promote the degradation of the rRNA and turnover of the incomplete precursor particle  
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(Silvers and Champney 2005). In S. aureus RN 4220 cells with an inducible erm gene 
erythromycin also stalled the assembly of the nascent subunit (Champney, Chittum, and 
Tober 2003). However, in this case the stalled precursor particle would be a substrate for 
the erm methyltransferase enzyme. Methylation of the 23S rRNA in the precursor particle 
relieves the assembly inhibition, permitting the synthesis of methylated particles that are 
resistant to the inhibitory effects of the antibiotic. This assembly sequence explains why 
mature 50S subunits are not methyltransferase substrates.   
 
Purification and detection of ermE methyltransferase   
          The ermE methyltransferase was purified from a cloned vector perm60 with a  
C-terminal histidine tag. Comparison studies with an untagged ermE have shown that the 
HIS6 sequence tag does not detectably affect the ability of the enzyme to methylate RNA 
substrates (Douthwaite et.al. 1998). In these studies, SDS polyacrylamide gel 
electrophoresis was used to assess the purity of the enzyme. In the current studies after 
its purification on Ni-affinity chromatography column and elution with 250 mM imidazole, 
ermE methyltrasnferase was detected by Western blotting using an anti His6 monoclonal 
antibody (Figure 25). 
         The cloned methyltransferase (calculated molecular weight 43.6 KDa) migrated 
slightly faster than the ovalbumin marker protein (45 KDa) on the gel.  As expected in the 
crude and eluate fractions, a strong signal was obtained at the corresponding molecular 
weight of the enzyme. There was some non-specific elution of the enzyme in the absence 
of imidazole in the wash fraction but this signal was minimal. Importantly, there was no 
breakdown of the enzyme as suggested by the single band in the eluate fraction. Thus 
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Western blotting provides evidence for the purification of an integral ermE 
methyltransferase.   
 
ermE methyltransferase Activity Assay 
            The current studies with ermE methyltransferase are an extension to the previous 
studies with the ermC methyltransferase (Champney et al. 2003). Moreover, those 
studies were conducted with a crude extract of ermC methyltransferase as a preliminary 
probe into the true nature of in vivo erm substrate. In the current studies, assays were 
carried out with the purified eluate fraction of the Ni-affinity column. 23S rRNA, a 50S 
precursor particle, 50S subunits, 30S subunits, and 16S rRNA were all tested as 
substrates. Figure 26 indicated that purified 23S rRNA was the functional substrate for the 
enzyme as also shown by other studies (Skinner et al 1983, Weisblum 1995). It was also 
observed that the 50S precursor particle showed considerable methylation. Significantly, 
fully assembled 50S subunits failed to act as substrates although they contain 23S rRNA 
and the full complement of 50S proteins. However, 30S subunits and 16S rRNA were not 
methylated by the enzyme as well. 
            These findings essentially confirm the results obtained earlier with ermC. Based 
on these observations, it was hypothesized that the true in vivo substrate for ermE 
methyltransferase is the 50S subunit precursor particle that sediments along with the 
30S subunits on the sucrose gradients of the lysates from erythromycin treated  
S. aureus cells. It was also proposed that this precursor particle is composed of 23S 
rRNA and a subset of 50S ribosomal proteins essential for erm methylation. 
           The ermE methyltransferase assay results (Figure 26) are consistent with this 
hypothesis, and the results showed that maximum level of methylation occurred with 
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23S rRNA as the substrate and that the 50S precursor particle that showed a 
considerable degree of methylation. Poor methylation activities were observed with 50S 
and 30S ribosomal subunits and 16S rRNA. Significantly, the absence of protein free 
23S rRNA in the cells and the failure of fully assembled 50S subunits to act as substrate 
further substantiate the hypothesis that the 50S precursor particle as the true in vivo 
substrate for ermE methyltransferase. 
             These results draw attention to the conformation of 23S rRNA needed for ermE 
recognition. Enzyme activity depends both on the primary and secondary structure 
around the methylation site (Kovalic 1995, Nielsen et al. 1999, Villsen et al. 1999).  The 
requirement for high enzyme fidelity in recognizing a single target amongst an array of 
rRNA nucleotides reveals the uniqueness of this rRNA region and thus sequence 
specificity. The nucleotides at positions 1055 and 2058 to 2061 are conserved over 95% 
(Villsen et al.  1999).  
          Studies of O’Farrell and Rife on 16S rRNA methylation using kasugamycin 
resistance showed that in E. coli a 30S ribosomal assembly intermediate serves as a 
substrate for KsgA, a dimethyltransferase, strongly support our findings (Thammana 
1974, O'Farrell et al. 2006). In E. coli, kasugamycin resistance results from a mutation 
at the ksgA locus due to the lack of the methylase activity (Helser 1971, Helser 1972, 
Zimmerman 1973). Ksg encodes for an adenosine dimethyltransferase that 
dimethylates A1518 and A1519 in the 16S rRNA of E. coli. It was shown that neither 
16S rRNA nor 30S subunits in a translationally active state were substrates for the 
enzyme in vitro (Thammana 1974, Desai and Rife 2006). In recent studies it was 
shown that KsgA recognizes a complicated substrate. Methylation occurs during 30S 
assembly, where a particle containing 16S rRNA along with 8 core proteins is the 
 101 
methylation substrate. Although KsgA can bind to naked 16S rRNA, it remained 
enzymatically inactive until a partially matured 30S subunit was assembled. The in 
vivo minimal substrate required 16S RNA plus the ribosomal proteins S4, S6, S8, S11, 
S15, S16, S17, and S18, suggesting that dimethylation of A1518 and A1519 might 
occur during a specific point during ribosome assembly. 
        The above conclusions were supported by numerous structural data of the 30S 
subunit in the active and inactive conformations. In the crystal structure of Thermus 
thermophilus 30S subunit in which the 30S was in an active conformation, A1518 and 
A1519 were well buried into the grove of helix 44 and, therefore, sequestered from KsgA. 
However, conversion to the inactive state exposed the same two nucleotides to the 
solvent.  
        Slot blot hybridization (Figure 15) identified the presence of 23S rRNA in the 50S 
precursor particle and sixteen large ribosomal proteins were found in this region by 
MALDI-TOF mass spectrometric analysis (Figure 21). Together, these results propose 
this 50S precursor as a particle analogous to the one identified earlier in E. coli (Usary 
and Champney 2001). It has all the components needed for erythromycin binding as well 
as for erm methylation, although the significance of individual proteins still needs to be 
elucidated. In the absence of a protein free 23S rRNA in the cells, these findings strongly 
support the current hypothesis of 50S ribosomal precursor particle being an in vivo 
substrate for ermE methyltransferase. 
 
Inhibition of ermE methylation by MLSB antibiotics: 
          MLSB drugs, represented by erythromycin, lincomyin, and virginiamycin S, share a 
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common binding site on the 50S subunits and hence on the 50S precursor particle. The 
peptidyltransferase domain on the 50S subunit is a common target for the MLS
 B 
antibiotics that includes the erm methylation site A2085 in the helix V of 23S rRNA. 
 MLS
 B drugs cause steric hindrance to the binding of erm methyltransferase and hence 
could act as inhibitors of the latter’s activity. Data from Figure 27 showed that this 
prediction was true. MLSB drugs inhibited ermE methyltransferase activity in a 
concentration dependent manner. Inhibition constants of all the three drugs were found to 
be similar.   
 
Competition Assays 
           In the inhibition curves, it was seen that the erm methylation activity was inhibited 
with the concentration of the MLS drugs. This is expected when there is a direct 
competition in the binding of both these agents to the 50S precursor particle. The protein 
free 23S rRNA and the 50S precursor particle containing 23S rRNA with a subset of 50S 
proteins are substrates for ermE methyltransferase. The methylation site A2085 is 
accessible for the enzyme action, whereas erythromycin binds to the 50S precursor 
particle and 50S subunits where the PTC in domain V is available for erythromycin 
binding. This transition suggests that 50S precursor particle, in the middle of the 
assembly sequence, has the all the sequence and conformation features needed for the 
binding of both the enzyme and the drug (Figure 31).  
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23S rRNA ---------------------------- 50S precursor -------------------------  50S subunits 
 
 
Figure 31 Model showing the interaction of erythromycin and ermE methyltransferase with 
the 50S precursor particle.  
 
            Another set of competition experiments is shown in Figures 28 and 29.  The 
results of Figure 28 indicate that at increasing concentrations, ermE methyltransferase 
displaced erythromycin from the 50S precursor particle resulting in increasing methylation 
levels.  Similar assays examining the binding of 14C erythromycin binding showed 
decreased erythromycin binding with increasing concentrations of ermE 
methyltransferase (Figure 29). Competition experiments indicated that the association 
constant (KM) of ermE methyltransferase is 330 fold higher than the inhibition constant 
(Ki) of erythromycin suggesting the requirement for a higher concentration of the drug to 
prevail over methylase. 
           Hence, competition between these two substrates for the 50S precursor particle is 
an obligatory outcome when both are present. The fine tuning of the competition depends 
on the kinetics of their binding. Erythromycin binds to the 50S precursor particle in a 1:1 
ratio resulting in every stalled precursor particle affectively having one drug molecule 
bound whereas a single ermE methyltransferase molecule can repeat catalysis cycles to 
methylate different 50S precursor particles making them MLS resistant. Thus, the  
stoichiometry of erythromycin binding and the catalysis of erm methylase are two very 
  Methylation Binding 
Competition 
Erythromycin 
       ermE 
methyltransferase 
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important factors that determine which one binds to the 50S precursor particle.   
          Competition between erythromycin and ermE methyltransferase at the PTC was 
studied for the first time. These in vitro kinetic studies yielded a better understanding of 
the interaction of the antibiotic and the enzyme at their binding site. Studies of this nature 
provide important clues about the interplay between the drug and the enzyme in the erm 
producing strains leading to erythromycin resistance.  
         Inhibitors of erm methyltransferase have been studied to sensitize bacteria that 
are resistant to erythromycin in vivo and in vitro. In this regard, it is of interest to note 
that S- Adenosyl-L-homocysteine, the metabolic product of S-adenosyl-L-methionine 
after the methyl group transfer, is a naturally occurring inhibitor of erm 
methyltransferase with a Ki of 40 µM. Fesik and coworkers (Katz 1999) have screened 
a small library of heterocyclic compounds for their anti erm activity. Hannesian and 
Sgarbi designed mimics of S-adenosyl-L-homocysteine as potential inhibitors of erm 
methyltransferases (Hanessian and Sgarbi 2000). Sinefungin is another general 
inhibitor of methyltransferases, which is a natural nucleoside occurring in 
Streptpmyces griseolus. Chemically, sinefungin is S-adenosyl ornithine (Goldman and 
Kadam 1989). 
        In view of the limited clinical success of these inhibitors, it is important to further 
understand the true cellular target for erm methylase and to know if the enzyme can 
actively displace bound erythromycin from the precursor substrate. Current studies 
yielded information needed for a more rational approach for antibiotic development.  
and therapy strategies against the clinically important pathogen S. aureus.                                                  
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APPENDIX 
ABBREVIATIONS 
 
     PTC………………………………. …   Peptidyl Transferase Center 
 
     IDV……………………………………   Integration Density Value 
 
     Ec……………………………………..   Escherichia coli 
 
     Dr……………………………………..    Deinococcus radiodurans 
 
     Erm…………………………………..    Erythromycin Resistance Methylase 
 
     rRNA…………………………………    Ribosomal RNA 
 
     MLSB…………………………………    Macrolide, Lincosamide, Streptogramin B 
 
     30S…………………………………..    Small subunit of ribosome 
         
     50S …………………………………..    Large subunit of ribosome 
 
     SAS buffer……………………………   S. aureus subunit buffer 
 
     R buffer ………………………………   Ribosome buffer 
 
     IC50……………………………………    50% Inhibition Concentration 
 
    TSB……………………………………    Tryptic Soy Broth 
 
    SDS……………………………………    Sodium dodecyl sulfate 
 
    PMSF…………………………………..   Phenylmethylsulfonylfluoride 
 
    TCA…………………………………….   Trichloroacetic acid 
 
    SAM…………………………………….   S-Adenosyl Methionine 
 
    PAGE…………………………………..    Polyacrylamide Gel Electrophoresis 
  
    MES…………………………………….    2-[N-Morpholino]ethane sulfonic acid 
  
    TE……………………………………….    Tris EDTA buffer 
 
    TEMED………………………………….   Tetramethylethylenediamine 
 119 
 
    APS…………………………………….    Ammonium per sulfate 
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